

Battelle Memorial Institute and Subsidiaries

Consolidated Financial Statements as of and for the Years Ended September 30, 2022 and 2021, Schedule of Expenditures of Federal Awards for the Year Ended September 30, 2022 and Report on Internal Control over Consolidated Financial Reporting and on Compliance and Other Matters Based on an Audit of the Consolidated Financial Statements Performed in Accordance with Government Auditing Standards and Report on Compliance for Each Major Federal Program and Report on Internal Control over Compliance and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES

TABLE OF CONTENTS

	Page
Part I. INDEPENDENT AUDITOR'S REPORT	1–2
Part II. CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED SEPTEMBER 30, 2022 AND 2021:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Comprehensive Income	5
Consolidated Statements of Equity	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8–33
Schedule of Expenditures of Federal Awards for the Year Ended September 30, 2022	34–47
Notes to Schedule of Expenditures of Federal Awards for the Year Ended September 30, 2022	48–49
Report on Internal Control Over Consolidated Financial Reporting and on Compliance and Other Matters Based on an Audit of Consolidated Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	50–51
Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance	52–54
Schedule of Findings and Questioned Costs for the Year Ended September 30, 2022	55–58

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Battelle Memorial Institute and Subsidiaries
Columbus, Ohio:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Battelle Memorial Institute and subsidiaries (the "Company"), which comprise the consolidated balance sheets as of September 30, 2022 and 2021, and the related consolidated statements of operations, comprehensive income, equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of September 30, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Battelle and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the consolidated financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated November 30, 2022 on our consideration of Battelle's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Battelle's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Battelle's internal control over financial reporting and compliance.

Deloitte & Touche LLP

November 30, 2022

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Consolidated Balance Sheets

(In thousands)	September 30,	
	2022	2021
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 381,090	\$ 310,068
Available-for-sale debt securities	2,572	287
Restricted cash restricted and cash equivalents	23,267	14,156
Accounts receivable, net	285,647	246,629
Prepayments and other current assets	28,001	36,609
Prepayments and other current assets, restricted	1,539	3,619
Assets held for sale	4,356	5,894
Total current assets	726,472	617,262
Noncurrent Assets:		
Available-for-sale debt securities	206,372	231,654
Equity securities	298,808	359,261
Equity method investments	104,990	104,875
Other investments	66,665	49,525
Property and equipment, net	166,393	180,235
Pension and postretirement plans benefit	22,459	93,583
Goodwill	14,913	17,399
Other intangibles and other assets, net	39,935	44,074
Total Assets	\$ 1,647,007	\$ 1,697,868
LIABILITIES AND EQUITY		
Current Liabilities:		
Accounts payable	77,912	56,048
Accrued compensation and benefits	80,008	58,453
Current notes and debts payable	-	40,000
Advance payments from clients	65,014	58,691
Accrued expenses and other liabilities	58,464	84,351
Total current liabilities	281,398	297,543
Noncurrent Liabilities:		
Long-term notes and debts payable	305,000	265,000
Long-term benefit-related liabilities	24,507	20,967
Accrued pension and postretirement benefits	1,468	121,218
Other liabilities	18,331	26,548
Total noncurrent liabilities	349,306	433,733
Equity:		
Retained for purposes of the Will of Gordon Battelle	1,180,150	1,133,309
Accumulated other comprehensive loss:		
Net unrealized (loss) gain on available-for-sale securities	(21,540)	6,008
Net unrealized loss on foreign currency translation	(5,609)	(1,459)
Pension and postretirement benefits	(160,308)	(194,549)
Total parent equity	992,693	943,309
Noncontrolling interests	23,610	23,283
Total equity	1,016,303	966,592
Total liabilities and equity	\$ 1,647,007	\$ 1,697,868

See notes to consolidated financial statements.

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Consolidated Statements of Operations

(In thousands)	Years Ended September 30,	
	2022	2021
Revenue:		
Revenue from operations	\$ 11,060,637	\$ 10,019,102
Other revenues	<u>9,122</u>	<u>7,548</u>
Total revenues	<u>11,069,759</u>	<u>10,026,650</u>
Operating Expense:		
Operating expense	10,977,201	9,911,536
Other operating income (see Note 4)	18,640	55,100
Operating Income	<u>111,198</u>	<u>170,214</u>
Nonoperating Income (expense):		
Investment income, net	(35,540)	64,653
Net periodic pension and postretirement income (expense), less service costs	17,913	9,156
Distribution expense	(24,461)	(29,065)
Interest expense	(9,629)	(9,634)
Other, net	<u>11,859</u>	<u>8,826</u>
Total nonoperating income, net	<u>(39,858)</u>	<u>43,936</u>
Income Before Income Tax Provision and Noncontrolling Interests	71,340	214,150
Income Tax Provision	<u>(1,565)</u>	<u>(4,449)</u>
Net Income	69,775	209,701
Net Income Attributable to Noncontrolling Interests	<u>(22,934)</u>	<u>(22,650)</u>
Net Income Attributable to Parent	<u>\$ 46,841</u>	<u>\$ 187,051</u>

See notes to consolidated financial statements.

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Consolidated Statements of Comprehensive Income

(In thousands)	Years Ended September 30,	
	2022	2021
Net Income Attributable to Parent	<u>\$ 46,841</u>	<u>\$ 187,051</u>
Net Income Attributable to Noncontrolling Interests	<u>22,934</u>	<u>22,650</u>
Other comprehensive (loss) income:		
Unrealized gain (loss) on foreign currency translation	(4,150)	821
Net unrealized gain (loss) on available-for-sale securities	(27,548)	7,186
Change in actuarial gain (loss)	47,718	(15,664)
Prior service cost arising during the period, net	<u>(13,477)</u>	<u>(6,450)</u>
Total Other Comprehensive Gain (Loss)	2,543	(14,107)
Comprehensive Income	<u>\$ 72,318</u>	<u>\$ 195,594</u>

See notes to consolidated financial statements.

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Consolidated Statements of Equity

(In thousands)	Retained for Scientific and Educational Purposes of the Will of Gordon Battelle	Accumulated Other Comprehensive Loss	Noncontrolling Interests	Total
Balance at September 30, 2020	\$ 946,258	\$ (175,893)	\$ 23,204	\$ 793,569
Comprehensive income, net	187,051	(14,107)	22,650	195,594
Distributions to noncontrolling interests	-	-	(22,571)	(22,571)
Balance at September 30, 2021	1,133,309	(190,000)	23,283	966,592
Comprehensive income, net	46,841	2,543	22,934	72,318
Distributions to noncontrolling interests	-	-	(22,607)	(22,607)
Balance at September 30, 2022	<u>\$ 1,180,150</u>	<u>\$ (187,457)</u>	<u>\$ 23,610</u>	<u>\$ 1,016,303</u>

See notes to consolidated financial statements.

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Consolidated Statements of Cash Flows

(In thousands)	Years Ended September 30,	
	2022	2021
Cash Flows From Operating Activities:		
Net income	\$ 69,775	\$ 209,701
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation of property and equipment	24,129	26,706
Amortization of goodwill and other intangible assets	2,876	2,876
Deferred taxes	(251)	2,487
Bad debt expense	461	-
Unrealized loss / (gain) on equity securities	74,324	(50,112)
(Gain) / loss on other investments, net	(33,623)	(61,422)
(Gain) / loss on disposal of property and equipment	394	615
(Gain) / loss on sale of property and equipment	(8,863)	(8,200)
Impairment	1,263	-
Pension and postretirement benefits contributions	(174)	(75,181)
Pension and postretirement benefits credit	(14,208)	(4,296)
Changes in operating assets and liabilities:		
Accounts receivable	(52,525)	32,520
Prepayments and other current assets	8,608	(6,453)
Other current assets - restricted	2,080	(1,080)
Intangibles and other assets	3,748	(6,782)
Accounts payable	19,688	(9,967)
Payroll and other benefit-related liabilities	25,092	6,107
Advance payments from clients	8,408	5,563
Accrued expenses and other liabilities	(4,478)	2,182
Net cash provided by operating activities	126,724	65,264
Cash Flows From Investing Activities:		
Additions to property and equipment	(11,184)	(20,735)
Proceeds from distribution of property and equipment	11,094	10,017
(Gain) / loss on sales of securities, net	(8,230)	1,782
Proceeds from sales and maturities of securities	247,034	248,429
Purchase of securities	(257,272)	(217,710)
Settlement of derivatives	-	(35,189)
Distributions from other investments	10,258	15,303
Contributions to other investments	(11,534)	(16,570)
Net cash used in investing activities	(19,834)	(14,673)
Cash Flows From Financing Activities:		
Proceeds from notes payable	40,000	65,000
Payments of notes payable	(40,000)	-
Distributions to noncontrolling interests	(22,607)	(22,571)
Net cash used in financing activities	(22,607)	42,429
Effect of Exchange Rate Changes On Cash and Cash Equivalents	(4,150)	821
Net Increase in Cash, Cash Equivalents, and Restricted Cash	80,133	93,841
Cash, cash equivalents, and restricted cash at beginning of year	324,224	230,383
Cash, cash equivalents, and restricted cash at end of year	\$ 404,357	\$ 324,224

See notes to consolidated financial statements.

BATTELLE MEMORIAL INSTITUTE AND SUBSIDIARIES
Notes to Consolidated Financial Statements

NOTE 1 – BUSINESS OVERVIEW

Battelle Memorial Institute (“Battelle” or the “Company”) is a nonprofit Ohio corporation headquartered in Columbus, Ohio, with offices throughout the United States and in foreign countries. Battelle was formed in 1925, pursuant to the Will of Gordon Battelle (the “Will”) for the purposes of using technology to deliver practical solutions to the problems of government and industry and of making distributions to charitable causes. Battelle’s primary source of revenue is from providing technology-based research, management, commercialization, and educational services to government and industrial clients.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Standards Updates Adopted

During fiscal 2022, the Company adopted the following Accounting Standards Updates (“ASU”):

ASU No. 2016-13, Measurement of Credit Losses on Financials Instruments (Topic 326)

ASU No. 2016-13 and subsequent updates eliminates the requirement that a credit loss on a financial instrument be “probable” prior to recognition. Instead, a valuation allowance will be recorded to reflect an entity’s current estimate of all expected credit losses, based on both historical and forecasted information related to an instrument. The standard is effective for annual periods beginning after December 15, 2022. The Company has determined the standard will not have a material impact on its consolidated financial statements.

No other accounting standard updates had a material impact on the Company.

Basis of Presentation

The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (US GAAP). The accompanying consolidated financial statements include all the Company’s wholly owned and financially or otherwise controlled subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation and figures are presented in thousands, unless otherwise stated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to estimated profitability of long-term contracts, indirect billing rates, allowances for doubtful accounts, inventories, fair value measurements and impairment of intangible assets and goodwill, pension benefits and liabilities and contingencies. These estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates.

Cash Equivalents

Cash equivalents include cash on hand and highly liquid investments having an original maturity of three months or less. Cash equivalents consist primarily of institutional money market funds and other short-term investments.

Available-for-Sale Debt Securities

Debt securities are classified as available for sale and are carried at fair value. Unrealized holding gains and losses, net of the related tax effect, on available-for-sale debt securities are excluded from net income and reported as other comprehensive income until realized. Realized gains and losses from the sale of available-for-sale debt securities are determined on a specific identification basis. Other-than-temporary declines in value below cost are recognized in net income. Battelle analyzes other-than-temporary impairments using certain criteria, including the amount of unrealized loss, length of holding period, and recent performance of the debt security. Interest income is recognized as earned.

Equity Securities

Equity securities are carried at fair value on the Company's Consolidated Balance Sheets, as either current or non-current based on Management's intent with the investments. Both unrealized holding gains and losses and realized gains and losses on equity securities are reported in Investment income, net within the Company's Consolidated Statements of Operations in the current period.

Restricted Cash

Restricted cash primarily consists of money market funds and other short-term investments with an initial term of less than ninety days that have restrictions on the use of those funds based on contractual requirements.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable include amounts billed and currently due from customers and unbilled costs. Unbilled receivables include amounts earned but not yet billed.

Receivables are stated at estimated realizable value and consist of costs and fees, substantially all of which are expected to be billed and collected within one year. Amounts billable also include rate variances that are billable upon negotiation of final indirect rates with the US government and, once billed, are subject to audit and approval by federal government representatives.

Receivables include an allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balance, which is charged to the provision for doubtful accounts. The allowance is calculated based on Battelle's history of write-offs, level of past-due accounts, economic status of the customers, and other known factors concerning the customers' current financial condition and ability to pay.

Assets Held for Sale

Assets are classified as held for sale in the period in which management commits to a plan to sell the asset, the asset is available for immediate sale in its present condition, an active program to locate a buyer has been initiated, the sale of the asset is probable, the asset is being actively marketed for sale at a price that is reasonable in relation to its fair value, and actions required to complete the sale indicate that it is unlikely that significant changes to the plan will be made or that the plan to sell will be withdrawn. At the time of classifying the asset as held for sale, the Company recognizes the asset at the lower of the carrying amount or the fair value, less the cost to sell, and ceases depreciation immediately. While the asset is classified as held for sale the Company reviews, at a minimum annually, whether the classification is appropriate. When the asset is sold, the Company removes the asset balance from the consolidated balance sheet in the year of the sale and records a gain or loss based on the sale price, less the recorded amount of the asset in the consolidated balance sheet at the time of sale.

Property and Equipment

Property and equipment are recorded at cost, including capitalized interest on construction in progress. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets.

The cost of software (including cloud-based software) purchased or internally developed is capitalized, as appropriate, and includes external direct costs of material and services (including certain implementation services) and payroll costs for employees devoting time to the software projects. These costs are amortized over a period of 5 or 10 years, if not a cloud-based software, or over the service period if a cloud-based software, beginning when the asset is substantially ready for use. Costs incurred during the preliminary project stage, as well as maintenance and training costs, are expensed as incurred.

Battelle reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When a triggering event occurs, Battelle will estimate the fair value of the asset group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset to estimate the fair value, a loss is recognized for any excess of the carrying amount over the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

Equity-Method Investments

When Battelle does not have a controlling financial interest in an entity but can exert significant influence over the entity's operating and financial policies, the investment is accounted for either (i) using the equity method of accounting or (ii) at fair value by electing the fair value option. Significant influence generally exists when Battelle owns 20% to 50% of the entity's common stock or in-substance common stock.

Pension and Other Postretirement Plans

Many of Battelle's employees are covered by defined benefit pension plans. US GAAP requires that the amounts recorded related to postretirement benefit plans be computed, based on service to date, using actuarial valuations that are based, in part, on certain key economic assumptions made, including the discount rate, the expected long-term rate of return on plan assets, and other actuarial assumptions, including participant longevity (also known as mortality) estimates, health care cost trend rates, and employee turnover, each, as appropriate, based on the nature of the plans.

A market-related value of plan assets, determined using actual asset gains or losses over the prior two-year period, is used to calculate the amount of deferred asset gains or losses to be amortized. These asset gains or losses, along with those resulting from adjustments to the benefit obligation, will be amortized to expense over the average future-service period of employees expected to receive benefits under the plans.

Battelle recognizes on a plan-by-plan basis the funded status of its postretirement benefit plans under US GAAP as either an asset recorded within other noncurrent assets or a liability recorded within noncurrent liabilities in the consolidated balance sheets. There is a corresponding noncash adjustment to accumulated other comprehensive loss, net of tax benefits, recorded as deferred tax assets. The US GAAP-funded status is measured as the difference between the fair value of the plan's assets and the benefit obligation of the plan. The funded status under the Employee Retirement Income Security Act of 1974, as amended by the Pension Protection Act of 2006, is calculated on a different basis than under US GAAP.

When a plan change occurs, the Company evaluates if the plan change constitutes an event that requires remeasurement of plan assets and obligations and records any corresponding impact on the consolidated financial statements for plan assets, obligations, accumulated other comprehensive income, or net periodic benefit cost, as appropriate.

The service cost component of net periodic pension and other postretirement costs is reported as Operating Costs within the Companies Consolidated Statement of Operations, while all other components of net periodic pension and other postretirement costs are reported in Net Periodic Pension and Other Postretirement Costs within Nonoperating Income (expense) within the Companies Consolidated Statement of Operations.

Goodwill

Goodwill results from business combinations and represents the excess of the purchase price over the fair value of acquired tangible assets and liabilities and identifiable intangible assets. Effective October 1, 2018, Battelle adopted ASU 2017-04 *Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment* which requires the Company to amortize existing and new goodwill over a 10-year straight-line basis, unless an alternative shorter amortization period is determined. Goodwill acquired through a business combination, reorganization, or an event resulting in fresh-start reporting is amortized on a straight-line basis over 10 years. The Company may revise the remaining useful life of goodwill upon the occurrence of events and changes in circumstances that warrant a revision to the remaining period of amortization. However, the amortization period is not to exceed 10 years.

Goodwill is separately evaluated for impairment at the reporting unit level if triggering events occur, which indicate that the fair value of the reporting unit may be below its carrying value. If triggering events occur, the Company either performs a quantitative test or assesses qualitative factors to determine if it is more likely than not that the fair value of the reporting unit is less than its carrying amount and if it is necessary to perform the quantitative two-step goodwill impairment test. If the Company performs the quantitative test, it compares the carrying value of the reporting unit to an estimate of the reporting unit's fair value to identify potential impairment. The estimate of the reporting unit's fair value is determined by weighing a discounted cash flow model and a market-related model using current industry information that involve significant unobservable inputs (Level 3 inputs). In determining the estimated future cash flows, the Company considers and applies certain estimates and judgments, including current and projected future levels of income based on management's plans, business trends, prospects, market and economic conditions, and market participant considerations. If the estimated fair value of the reporting unit is less than the carrying value, a second step is performed to determine the amount of the potential goodwill impairment. If impaired, goodwill is written down to its estimated implied fair value.

The gross carrying amount of goodwill, related accumulated amortization and amortization expense as of September 30 were as follows:

	2022	2021
Gross Goodwill	\$ 24,856	\$ 24,856
Accumulated Amortization	<u>9,943</u>	<u>7,457</u>
Net Goodwill	<u>\$ 14,913</u>	<u>\$ 17,399</u>
Amortization Expense	<u>\$ 2,486</u>	<u>\$ 2,486</u>

Environmental Matters

Battelle records a liability for environmental matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. The amount of liability recorded is based on estimated costs to be incurred for remediation at a particular site. Battelle does not discount the recorded liabilities as the amount and timing of future cash payments are not fixed or cannot be reliably determined. Environmental liabilities are recorded in the consolidated balance sheets in other liabilities.

Income Taxes

The Internal Revenue Service has previously determined that Battelle is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3), except for income arising from unrelated business activities. Certain Battelle subsidiaries file individually as taxable legal entities. Accordingly, the accompanying consolidated financial statements include tax provisions for consolidated subsidiaries and for certain federal, state, local, and foreign taxes. Other subsidiaries, including Brookhaven Science Associates, LLC; UT-Battelle, LLC; and Triad National Security, LLC (“Triad”) are treated as partnerships for federal income tax purposes. Accordingly, profits and losses are passed directly to partners for inclusion in their income tax returns.

For Battelle's taxable subsidiaries or nonexempt state, local, and foreign jurisdictions, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled and are recorded as noncurrent in the Company's consolidated balance sheets. The Company's deferred tax assets and liabilities are classified as long-term. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, or services have been rendered, the fee is fixed or determinable, and collectability is reasonably assured.

Substantially, all revenue is derived from services and solutions provided to the US government and its agencies (collectively, the "U.S. Government"). Battelle generates most of its revenue from three different types of contractual arrangements: cost reimbursable plus fee, time and materials, and fixed-price contracts.

Revenue on cost reimbursable plus fee contracts is recognized as services are performed, generally based on the allowable costs incurred during the period, plus any recognizable earned fees.

Revenue earned under time and materials contracts is recognized as labor hours are worked based on contractually billable rates to the client. Direct costs on time and materials contracts are expensed as incurred.

Revenue on fixed-price contracts is primarily recognized over time based on actual costs incurred (input method) relative to total estimated costs for the contract. Periodically, the estimated costs are updated during the term of the contract and may result in revision of recognized revenue and estimated costs in the period in which the changes in estimated costs are identified.

Contract accounting requires significant judgment relative to assessing risks, estimating contract revenue and costs, making assumptions for schedule and technical issues, and assessing the probability of funding by the contracting agency. Due to the size and nature of many of the contracts, developing total revenue and cost at completion estimates requires the use of significant judgment. Estimates of total contract revenue and costs are monitored during the term of the contract and are subject to revision as the contract progresses. Anticipated losses on contracts are recognized in the period they are deemed probable and can be reasonably estimated.

The Company recognizes revenue on its service-based contracts primarily over time as there is continuous transfer of control to the customer over the duration of the contract as the Company performs the promised services. For U.S. government contracts, continuous transfer of control to the customer is evidenced by clauses in the contract that allow the customer to unilaterally terminate the contract for convenience, pay for costs incurred plus a reasonable profit and take control of any work-in-process. Similarly, for non-U.S. government contracts, the customer typically controls the work-in-process as evidenced by rights to payment for work performed to date plus a reasonable profit to deliver products or services that do not have an alternate use to the Company. Anticipated losses on service-based contracts are recognized when known.

Certain of the Company's cost-plus and fixed-price contracts contain award fees, incentive fees or other provisions that may either increase or decrease the transaction price. These variable amounts generally are awarded upon achievement of certain performance metrics, program milestones or cost targets and can be based upon customer discretion. The Company estimates variable consideration at the most probable amount that it expects to be entitled to, based on the assessment of the contractual variable fee criteria, complexity of work and related risks, extent of customer discretion, amount of variable consideration received historically and the potential of significant reversal of revenue.

Contracts with the U.S. government are subject to the Federal Acquisition Regulation (“FAR”) and priced on estimated or actual costs of providing the goods or services. The FAR provides guidance on types of costs that are allowable in establishing prices for goods and services provided to the U.S. government and its agencies. Each contract is priced and bid separately. Pricing for non-U.S. government agencies and commercial customers is based on specific negotiations with each customer. In circumstances where the standalone selling price is not directly observable, we estimate the standalone selling price using the expected cost-plus margin approach.

Contract costs on U.S. Government contracts, including indirect costs, are subject to audit by the federal government and adjustment pursuant to negotiations between Battelle and government representatives. Battelle’s federal contract indirect costs have been agreed upon through fiscal year 2020. Fiscal year 2021 indirect cost audits are in process. Contract revenue on U.S. Government contracts has been recorded in amounts that are expected to be realized upon final settlement. In the opinion of management, the outcome of these matters will not have a material effect on the consolidated financial statements in subsequent periods for federal government audits not yet started or completed.

Battelle occasionally proceeds with work based on customer direction prior to the completion and signing of formal contract documents. Battelle has a formal review process for approving any such work. Revenue associated with such work is recognized only when it can be reliably estimated, and realization is probable. Battelle bases its estimates on previous experiences with the customer, communications with the customer regarding funding status, and its knowledge of available funding for the contract or program.

For certain performance obligations where the Company is not primarily responsible for fulfilling the promise to provide the goods or service to the customer, does not have inventory risk and does not have discretion in establishing the price for the goods or service, the Company recognizes revenue on a net basis.

Royalties, license, and patent income are recognized when earned and collectible.

Internal Research and Development Expense

Internal research and development expense include expenses, such as equipment purchases, facility expenses, and personnel costs, which are incurred on behalf of research and development activities. Internal research and development costs are generally expensed as incurred, with purchases of fixed and intangible assets being capitalized if they provide for alternative future uses.

Concentrations of Credit Risk

Financial instruments that potentially subject Battelle to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. Battelle’s cash equivalents are generally invested in prime or US Government money market funds, which minimizes the credit risk. Battelle believes that credit risk for accounts receivable is limited as the receivables are primarily due from the US Government.

Distributions

Commitments for unconditionally pledged charitable distributions are accrued when committed.

Standards Effective in Future Years

Battelle has not identified any Accounting Standards Updates for future year adoption.

NOTE 3 – REVENUE RECOGNITION

Disaggregation of Revenues:

The Company disaggregates revenues by customer-type (government, commercial or national laboratory), as well as by the timing of transfer of goods and services (at a point in time or over time). These categories represent how the nature, timing and uncertainty of revenues and cash flows are affected by the contract procurement environment and timing of the provision of such goods and services for which revenue is earned. Total Revenues of \$11,069,759 and \$10,026,650, for the years ended September 30, 2022 and 2021 respectively, as reported in the Company’s Consolidated Statements of Operations, represent revenue from contracts with customers in accordance with ASC 606.

Revenue from Operations

	2022	2021
Government	\$ 10,946,520	\$ 9,915,564
Commercial	114,117	103,538
Total Revenue from Operations	<u>\$ 11,060,637</u>	<u>\$ 10,019,102</u>

National Laboratories

Battelle manages and operates six national laboratories for the Department of Energy (“DoE”), as well as the National Biodefense Analysis and Countermeasures Center (“NBACC”) for the Department of Homeland Securities. Revenues earned through the management and operations of these locations represent the majority of Battelle’s government source revenues. The following are the Battelle-managed and operated national laboratories, and NBACC, along with their respective revenues, for the years ended September 30:

National Laboratory	Location	Contract Expiration	2022	2021
Los Alamos National Laboratory	Los Alamos, New Mexico	September 2028	\$ 3,814,950	\$ 3,267,976
Oak Ridge National Laboratory	Oak Ridge, Tennessee	March 2025	2,327,874	2,253,401
Idaho National Laboratory	Idaho Falls, Idaho	September 2024	1,630,232	1,572,181
Pacific Northwest National Laboratory	Richland, Washington	September 2027	1,332,878	1,244,664
Brookhaven National Laboratory	Upton, New York	January 2025	616,066	604,682
Savannah River National Laboratory	Jackson, South Carolina	December 2025	333,921	88,399
National Biodefense Analysis and Countermeasures Center	Frederick, Maryland	September 2025	45,870	44,968
Total			<u>\$ 10,101,791</u>	<u>\$ 9,076,271</u>

Research and Development

Battelle performs research and development work for government and commercial clients, providing technology-based research, commercialization, and educational services. These research and development projects vary significantly in nature from client to client, are often accounted for using the over time method for revenue recognition and include significant judgement over the related estimates at completion. Revenues and cost of operations from research and development projects were as follows for the year ended September 30:

	2022	2021
Revenues from operations	\$ 958,846	\$ 942,832
Costs of operations	\$ 923,458	\$ 828,122

Timing of transfer of goods and services

The majority of Battelle's revenue are earned over time as the provision of research and laboratory services are performed. In addition, most of the Company's revenues are derived from work performed for government customers in which transfer of ownership to the customer is deemed to have occurred as work is in process.

	<u>2022</u>	<u>2021</u>
Over time	\$ 11,061,828	\$ 10,011,535
Point-in-time	<u>7,931</u>	<u>15,115</u>
Total	<u>\$ 11,069,759</u>	<u>\$ 10,026,650</u>

Receivables, Contract Assets and Contract Liabilities:

The Company's performance obligations are satisfied either over time as work progresses or at a point in time. Firm-fixed-price contracts are typically billed to the customer using milestone payments while cost-reimbursable and time-and-materials contracts are typically billed to the customer on a monthly or bi-weekly basis as indicated by the negotiated billing terms and conditions of the contract. As a result, for each of the company's contracts, the timing of revenue recognition, customer billings and cash collections results in a net contract asset or liability at the end of each reporting period. Contract assets include unbilled receivables, which represents the amount of revenue earned and recognized that exceeds the amount billed to the customer at year-end. Contract liabilities consist of advance payments from customers that have been provided to Battelle prior to the associated revenue being earned.

Accounts Receivable

	<u>As of September 30,</u>	
	<u>2022</u>	<u>2021</u>
Government accounts receivable:		
Billed	\$ 59,980	\$ 75,870
Unbilled	223,068	124,476
Commercial accounts receivable:		
Billed	16,180	19,569
Unbilled	14,393	37,010
Other	<u>11,143</u>	<u>16,739</u>
Total accounts receivable	324,764	273,664
Less provision for doubtful accounts	(4,983)	(6,251)
Less provision for revenue reserve	<u>(34,134)</u>	<u>(20,784)</u>
Accounts receivable, net	<u>\$ 285,647</u>	<u>\$ 246,629</u>
Contract assets	274,504	229,890
Contract liabilities	65,014	58,691

Contracts assets comprised primarily of billed and unbilled accounts receivable. Contract liabilities comprised primarily of advance payments received from customers.

NOTE 4 – INVESTMENTS

Equity Investments

The fair value of Battelle’s equity investments that were classified within Equity investments in the accompanying Consolidated Balance Sheets as of September 30 were as follows:

	<u>As of the year ended September 30,</u>	
	<u>2022</u>	<u>2021</u>
Battelle Investment Portfolio - equity securities	\$ 286,961	\$ 345,637
Rabbi Trusts	5,531	6,156
Supplemental Executive Retirement Plan	<u>6,316</u>	<u>7,468</u>
Total	<u>\$ 298,808</u>	<u>\$ 359,261</u>

Battelle has four Rabbi Trust Plans, representing Non-Qualified Retirement Plans of which one is open for active participants as of September 30, 2022. Battelle’s Supplemental Executive Retirement Plan (“SERP”) covers benefits for applicable Battelle and PNNL employees that retired prior to 2001.

The fair value of Battelle’s equity investments that were classified within Other Investments in the accompanying Consolidated Balance Sheets as of September 30 were as follows:

	<u>2022</u>			<u>2021</u>		
	<u>Inception-to-date Commitments</u>	<u>Inception-to-date Capital Called</u>	<u>Fair Value</u>	<u>Inception-to-date Commitments</u>	<u>Inception-to-date Capital Called</u>	<u>Fair Value</u>
Privately Managed Equity Funds	\$ 68,670	\$ 52,278	\$ 31,330	\$ 68,670	\$ 50,579	\$ 26,013
Venture Funds	<u>50,750</u>	<u>39,642</u>	<u>30,233</u>	<u>54,750</u>	<u>39,339</u>	<u>23,138</u>
Total	<u>\$ 119,420</u>	<u>\$ 91,920</u>	<u>\$ 61,563</u>	<u>\$ 123,420</u>	<u>\$ 89,918</u>	<u>\$ 49,151</u>

Battelle’s investment guidelines provide for up to eighteen percent of the total investment portfolio be invested in commercial venture funds and/or private equity.

Equity Method Investments

The fair value of Battelle’s equity method investments in the accompanying Consolidated Balance Sheets as of September 30, 2022 and 2021, were as follows:

	<u>As of the year ended September 30,</u>	
	<u>2022</u>	<u>2021</u>
AmplifyBio, LLC	\$ 100,000	\$ 100,000
Alliance for Sustainable Energy, LLC (“Alliance”)	1,990	1,875
Allonnia, LLC	<u>3,000</u>	<u>3,000</u>
Total	<u>\$ 104,990</u>	<u>\$ 104,875</u>

AmplifyBio

In April 2021, Battelle finalized an agreement with Viking Global Investors, LP, Casdin Capital, LLP, and Narya Capital Fund GP I, LLC (a related party) to form AmplifyBio, LLC (“AmplifyBio”) with a valuation of \$180,000. In exchange for a contribution of assets of \$15,025, assumed liabilities of \$20,000 and incurred transaction costs of \$9,875, Battelle received 10,000,000 Class A units of AmplifyBio valued at \$100,000. In August 2022, Battelle recognized a net operating gain from the release of contingent consideration of \$18,640 after AmplifyBio met its 12-month revenue target (presented as “other operating income” in the Consolidated Statements of Operations) and investors purchased all of the additional \$20,000 of Class A units available for purchase under the Supplemental Purchase and Liquidity Rights Agreement. The assumptions used in measuring fair value of the assets are considered level 3 inputs, which include market comparable information and discounted cash flows based on assumptions that market participants would use.

Available-for-sale debt securities

Battelle’s available-for-sale debt securities are comprised of debt securities held and managed within Battelle’s investment portfolio fund as well as the debt security investments of Research Insurance Company Limited (“RICL”), a wholly owned subsidiary of Battelle. RICL currently covers professional errors & omissions liability, environmental impairment liability, workers’ compensation, property, and multiple other liability exposures for Battelle and its subsidiaries as well as other unrelated business entities.

Battelle records realized gains and losses on available-for-sale debt securities in Investment income within the accompanying Consolidated Statement of Operations. Unrealized gains and losses on available-for-sale debt securities are recorded in Other Comprehensive Income within the accompanying Consolidated Statements of Comprehensive Income.

	As of and for the year ended September 30, 2022				
	Gross Realized Gain	Gross Realized Loss	Gross Unrealized Gain	Gross Unrealized Loss	Fair Value
Battelle Investment Portfolio - Fixed Income Securities	\$ 1,530	\$ (434)	\$ 152	\$ (7,096)	\$ 102,884
RICL - Fixed Income Securities	377	(854)	288	(14,884)	106,060
Total	\$ 1,907	\$ (1,288)	\$ 440	\$ (21,980)	\$ 208,944

	As of and for the year ended September 30, 2021				
	Gross Realized Gain	Gross Realized Loss	Gross Unrealized Gain	Gross Unrealized Loss	Fair Value
Battelle Investment Portfolio - Fixed Income Securities	\$ 5,314	\$ (619)	\$ 2,790	\$ (508)	\$ 110,718
RICL - Fixed Income Securities	882	(111)	5,176	(1,452)	121,223
Total	\$ 6,196	\$ (730)	\$ 7,966	\$ (1,960)	\$ 231,941

Battelle's available-for-sale debt securities' amortized cost, gross unrealized gains and losses, and fair value, aggregated by investment category and maturity length, were as follows:

	As of September 30, 2022			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
US corporate debt securities:				
Maturing within one year	\$ 1,678	\$ 7	\$ (26)	\$ 1,659
Maturing between one and five years	25,374	-	(1,619)	23,755
Maturing between five and ten years	11,943	-	(1,717)	10,226
Maturing beyond ten years	4,417	8	(566)	3,859
US corporate bond fund securities:				
Maturing beyond ten years	-	-	-	-
US Government agency debt securities:				
Maturing within one year	736	1	-	737
Maturing between one and five years	20,187	5	(1,162)	19,030
Maturing between five and ten years	2,346	-	(220)	2,126
Maturing beyond ten years	16,600	2	(3,479)	13,123
Mortgage-backed securities:				
Maturing within one year	182	-	(6)	176
Maturing between one and five years	27,944	13	(1,976)	25,981
Maturing between five and ten years	30,138	17	(2,289)	27,866
Maturing beyond ten years	88,939	387	(8,920)	80,406
Total available-for-sale debt securities	230,484	440	(21,980)	208,944
Less current portion	2,596	8	(32)	2,572
Total available-for-sale debt securities—less current portion	\$ 227,888	\$ 432	\$ (21,948)	\$ 206,372

	As of September 30, 2021			
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
US corporate debt securities:				
Maturing within one year	\$ 267	\$ 2	\$ -	\$ 269
Maturing between one and five years	24,350	692	(43)	24,999
Maturing between five and ten years	13,210	670	(46)	13,834
Maturing beyond ten years	4,048	604	(22)	4,630
US corporate bond fund securities:				
Maturing beyond ten years	12,382	1,126	-	13,508
US Government agency debt securities:				
Maturing within one year	-	-	-	-
Maturing between one and five years	3,119	269	-	3,388
Maturing between five and ten years	3,150	289	(1)	3,438
Maturing beyond ten years	16,194	1,575	(193)	17,576
Mortgage-backed securities:				
Maturing within one year	45	-	(27)	18
Maturing between one and five years	22,984	215	(65)	23,134
Maturing between five and ten years	35,294	464	(255)	35,503
Maturing beyond ten years	90,892	2,060	(1,308)	91,644
Total available-for-sale debt securities	225,935	7,966	(1,960)	231,941
Less current portion	312	2	(27)	287
Total available-for-sale debt securities—less current portion	\$ 225,623	\$ 7,964	\$ (1,933)	\$ 231,654

Battelle's available-for-sale debt securities' gross unrealized losses and fair value, aggregated by investment category and length of time that individual securities have been in continuous unrealized loss positions, were as follows:

	As of September 30, 2022					
	Less than 12 Months		12 Months or Longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
US corporate debt securities:						
Maturing within one year	\$ -	\$ -	\$ 1,552	\$ (26)	\$ 1,552	\$ (26)
Maturing between one and five years	7,198	(301)	16,497	(1,319)	23,695	(1,620)
Maturing between five and ten years	3,491	(371)	6,735	(1,346)	10,226	(1,717)
Maturing beyond ten years	1,319	(115)	2,223	(451)	3,542	(566)
US corporate bond funds:						
Maturing beyond ten years	-	-	-	-	-	-
US Government agency debt securities:						
Maturing between one and five years	15,772	(1,046)	2,700	(116)	18,472	(1,162)
Maturing between five and ten years	33	(4)	2,094	(215)	2,127	(219)
Maturing beyond ten years	2,633	(835)	10,458	(2,644)	13,091	(3,479)
Mortgage-backed securities:						
Maturing within one year	-	-	176	(6)	176	(6)
Maturing between one and five years	10,840	(894)	14,515	(1,082)	25,355	(1,976)
Maturing between five and ten years	13,640	(770)	12,811	(1,519)	26,451	(2,289)
Maturing beyond ten years	23,138	(1,162)	47,856	(7,758)	70,994	(8,920)
Total	\$ 78,064	\$ (5,498)	\$ 117,617	\$ (16,482)	\$ 195,681	\$ (21,980)

	As of September 30, 2021					
	Less than 12 Months		12 Months or Longer		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
US corporate debt securities:						
Maturing within one year	\$ 102	\$ -	\$ -	\$ -	\$ 102	\$ -
Maturing between one and five years	7,117	(32)	640	(17)	7,757	(49)
Maturing between five and ten years	1,329	(18)	1,204	(22)	2,533	(40)
Maturing beyond ten years	182	(13)	551	(8)	733	(21)
US corporate bond funds:						
Maturing beyond ten years	25	-	-	-	25	-
US Government agency debt securities:						
Maturing within one year	-	-	-	-	-	-
Maturing between five and ten years	148.00	(2)	-	-	148.00	(2)
Maturing beyond ten years	1,924	(112)	2,065	(80)	3,989	(192)
Mortgage-backed securities:						
Maturing within one year	-	-	18	(27)	18	(27)
Maturing between one and five years	12,318	(48)	1,209	(52)	13,527	(100)
Maturing between five and ten years	7,799	(27)	1,600	(301)	9,399	(328)
Maturing beyond ten years	13,979	(98)	12,268	(1,103)	26,247	(1,201)
Total	<u>\$ 44,923</u>	<u>\$ (350)</u>	<u>\$ 19,555</u>	<u>\$ (1,610)</u>	<u>\$ 64,478</u>	<u>\$ (1,960)</u>

NOTE 5 – FAIR VALUE OF FINANCIAL INSTRUMENTS

ASC 820, *Fair Value Measurements and Disclosures* (ASC 820), defines fair value and establishes a framework for measuring fair value. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. The three levels are defined as follows:

Level 1—Unadjusted quoted prices in active markets for identical assets and liabilities.

Level 2—Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

Level 3—Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

Asset Valuation Techniques—The following is a description of the valuation methodologies used for assets measured at fair value as of September 30, 2022 and 2021:

Debt Securities Available-for-Sale and Equity Securities—Valuations provided by a third party, who uses an external pricing service to estimate the fair value of the underlying investments. Battelle’s investment managers review and validate the prices utilized by the third party to determine fair value. Battelle receives audit reports of the broker’s operating controls and valuation process. The broker uses multiple pricing vendors for the securities. Certain debt securities are held at net asset value.

Fair values of financial assets measured on a recurring basis were categorized as follows:

Debt Securities

	As of September 30, 2022				As of September 30, 2021			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Available-for-sale debt securities:								
US government bonds	\$ -	\$ 34,773	\$ -	\$ 34,773	\$ -	\$ 24,046	\$ -	\$ 24,046
Common/collective Trust	-	-	-	-	-	-	-	-
Asset-backed securities	-	134,600	-	134,600	-	150,627	-	150,627
Corporate bonds	-	39,571	-	39,571	13,508	43,760	-	57,268
Total	\$ -	\$ 208,944	\$ -	\$ 208,944	\$ 13,508	\$ 218,433	\$ -	\$ 231,941

Equity Securities

	As of September 30, 2022				As of September 30, 2021			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Equity Securities:								
Corporate Stock	\$ 260,693	\$ -	\$ -	\$ 260,693	\$ 302,977	\$ -	\$ -	\$ 302,977
Common/collective Trust	11,848	-	-	11,848	13,625	-	-	13,625
Total	\$ 272,541	\$ -	\$ -	\$ 272,541	\$ 316,602	\$ -	\$ -	\$ 316,602

As of September 30, the following financial assets measured at net asset value per share were categorized as follows:

	Fair Value	
	2022	2021
Funds—common stock ⁽¹⁾	\$ 26,267	\$ 42,659
Funds—short-term investment ⁽²⁾	8,845	2,150
Money market funds	169,720	192,160
Total	\$ 204,832	\$ 236,969

⁽¹⁾ Funds—common stock—This class includes publicly traded equity investments, primarily stock. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.

⁽²⁾ Funds—short-term investments—This class includes short-term institutional money market funds, primarily composed of short-term government securities. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.

As of September 30, 2022, and 2021, the fair values of financial assets measured on a nonrecurring basis included primarily assets included in the asset impairment reviews. See Note 4 – Investments for description of assets, the amounts and basis of valuation. During fiscal period 2022 and fiscal period 2021, there were no transfers of financial assets between Level 1, Level 2, or Level 3.

NOTE 6 – PROPERTY AND EQUIPMENT AND LEASE COMMITMENTS

A summary of property and equipment as of September 30, was as follows:

	Useful Life (Years)	2022	2021
Land and improvements		\$ 5,556	\$ 7,776
Buildings and improvements	10–40	356,511	355,503
Furniture and equipment	2–40	158,008	148,166
Software	5–10	65,839	59,707
Construction in progress		<u>8,369</u>	<u>16,859</u>
Property and equipment—at cost		594,283	588,011
Accumulated depreciation		<u>(427,890)</u>	<u>(407,776)</u>
Total		<u>\$ 166,393</u>	<u>\$ 180,235</u>

Depreciation, including amortization of software and leasehold improvements, for 2022 and 2021 was \$24,129 and \$26,706, respectively.

NOTE 7 – ASSETS HELD FOR SALE

	As of 09/30/2022	Transfers	As of 09/30/2021	Transfers	As of 09/30/2020
PNNL properties	4,356	(1,538)	5,894	(1,980)	7,874
Hawker jet	<u>-</u>	<u>-</u>	<u>-</u>	<u>(785)</u>	<u>785</u>
Total	<u>\$ 4,356</u>	<u>\$ (1,538)</u>	<u>\$ 5,894</u>	<u>\$ (2,765)</u>	<u>\$ 8,659</u>

During 2017, Battelle entered into an agreement with the Department of Energy (“DoE”) to transfer certain buildings and land to the government in fiscal year 2018 and beyond. At the direction of the DoE, Battelle began cost recovery in accordance with the transfer agreement during 2017. All assets related to the future property sale were classified under assets held for sale and the related advance payments were classified as other current liabilities.

During 2022, Battelle closed the sale of Parcel B located in the Pacific Northwest National Laboratory campus in Richland, Washington, to the DoE for \$5,000. Included in assets held for sale as of September 30, 2022, was a balance of \$1,538 of fully cost reimbursed assets subsequently removed from assets held for sale at the time of closing resulting in a \$4,991 gain recorded in Other Non-Operating Income. Total carrying value of assets held for sale under this agreement are \$4,356 as of September 30, 2022.

In June 2020, Battelle reclassified a corporate plane (“Hawker Jet”) from Property and Equipment to Assets Held for Sale on Battelle’s Consolidated Balance Sheets. At the time of reclassification, the Hawker Jet had a carrying value of \$1,500 and a fair market value (less brokerage fees) of \$785. The Company recorded an impairment loss of \$715 within Restructuring and impairment costs in the Company’s Consolidated Statements of Operations. Battelle sold the asset in Q1 of FY2021 for \$1,083 recognizing a gain of \$299.

NOTE 8 – NOTES AND DEBTS PAYABLE

Notes and debts payable as of September 30, was as follows:

	2022		2021	
	Interest Rate	Outstanding Balance	Interest Rate	Outstanding Balance
Term loan A	3.26 %	\$ -	3.26 %	\$ 40,000
Term loan B	3.70	20,000	3.70	20,000
Term loan E	3.12	45,000	3.12	45,000
Term loan F	3.31	25,000	3.31	25,000
Term loan G	3.52	40,000	3.52	40,000
Term loan H	3.62	35,000	3.62	35,000
Term loan I	2.38	35,000	2.38	35,000
Term Loan J	2.50	25,000	2.50	25,000
Term Loan K	2.67	40,000	2.67	40,000
Term Loan L	2.75	15,000	-	-
Term Loan M	2.87	12,500	-	-
Term Loan N	2.87	12,500	-	-
Total		305,000		305,000
Less current portion of long-term debt		-		(40,000)
Long-term debt—net of current portion		<u>\$ 305,000</u>		<u>\$ 265,000</u>

Lines of Credit—Battelle occasionally borrows under three lines of credit in anticipation of cash demands. Under the three lines of credit, Battelle can borrow up to a total of \$160,000. All three lines of credit were extended in fiscal year 2022. The lines of credit A, B, and C, as amended, bear variable interest rates based on the Secured Overnight Financing Rate, plus 70bps, 70bps, and 80bps, respectively, and are due on September 14, 2023, February 28, 2023, and September 15, 2025, respectively. As of September 30, 2022, and 2021, the total availability from all of the lines of credit was \$159,411 and \$159,411, net of the letters of credit of \$589 and \$589, respectively. The lines of credit are unsecured; however, Battelle is required to maintain certain financial ratios. As of September 30, 2022, and 2021, Battelle believes it was in compliance with its financial ratio covenants.

Term Loans—Term loans A, B, E, F, G, H, I, J, K, L, M, and N, as amended, bear a fixed interest rate, which is payable semiannually and are due on April 13, 2022, April 25, 2024, July 10, 2027, August 5, 2026, August 5, 2029, August 5, 2031, May 19, 2030, October 15, 2035, October 15, 2040, April 12, 2034, April 12, 2037, and April 12, 2037, respectively.

The following table summarizes required future debt principal payments:

Years ending September 30,	
2023	\$ -
2024	20,000
2025	-
2026	25,000
2027	45,000
Thereafter	<u>215,000</u>
Total	<u>\$ 305,000</u>

NOTE 9 – OTHER INCOME AND EXPENSES

Other—net for the years ended September 30, consisted of the following:

	2022	2021
Gain on sale of real estate	\$ 8,863	\$ 7,718
Income from equity-method investments	2,297	2,423
Gain (loss) on distribution of assets	(86)	482
Other income (expense)	<u>785</u>	<u>(1,797)</u>
Total	<u>\$ 11,859</u>	<u>\$ 8,826</u>

NOTE 10 – INCOME TAXES

The Tax Cuts and Jobs Act (TCJA) was enacted on December 22, 2017. Among other things, the TCJA reduces the US federal corporate tax rate from 35% to 21% effective on January 1, 2018. The rate change is administratively effective at the beginning of fiscal year 2018, using a blended rate for the annual period. As of September 30, 2022, the 2018 to 2021 tax years remain open. At September 30, 2018, the Company remeasured the deferred tax asset and liability balances based on the rates at which they are expected to reverse in the future.

Income tax expense for the years ended September 30, consisted of the following:

	2022	2021
Current:		
U.S. federal	\$ 667	\$ 1,178
Foreign	1,000	619
State and local	<u>149</u>	<u>165</u>
Current income tax expense	<u>1,816</u>	<u>1,962</u>
Deferred:		
U.S. federal	(239)	2,457
State and local	<u>(12)</u>	<u>30</u>
Deferred income tax expense	<u>(251)</u>	<u>2,487</u>
Total expense	<u>\$ 1,565</u>	<u>\$ 4,449</u>

The tax effects of temporary differences that give rise to the deferred tax assets and deferred tax liabilities as of September 30, were as follows:

	2022	2021
Deferred tax assets:		
Other investments	\$ -	\$ 9
Compensated absences and other payroll-related liabilities		
Net operating loss carryforwards	7,149	6,723
General business credit carryforwards and other foreign	<u>1,189</u>	<u>1,394</u>
Total deferred tax assets before valuation allowance	8,338	8,126
Deferred tax liabilities - Investments	(4,592)	(4,416)
Net deferred tax assets before valuation allowance	<u>3,746</u>	<u>3,710</u>
Valuation allowance	<u>(5,999)</u>	<u>(6,213)</u>
Deferred tax assets (liabilities) — net	<u>\$ (2,253)</u>	<u>\$ (2,503)</u>

As of September 30, 2022, and 2021, Battelle’s taxable subsidiaries had tax net operating loss carryforwards generating deferred tax assets of \$7,149 and \$6,723, respectively, which are available to offset future taxable income, if any, through 2041. Based upon the level of historical taxable income and projections for future taxable income over the periods that the deferred tax assets are deductible, management believes it is more likely than not that Battelle’s taxable subsidiaries will not realize the entire benefits of these deductible differences. Therefore, the net operating loss carryforwards, along with other subsidiaries’ deferred tax assets, have a valuation allowance of \$5,999 and \$6,213 that have been recorded as of September 30, 2022 and 2021, respectively.

NOTE 11 – PENSION AND OTHER POSTRETIREMENT BENEFITS

Defined Contribution Plans—The Battelle Employees’ Savings Plan for the Battelle Columbus operations prescribes that employer-matching contributions are made at 50% of each individual employee’s contribution, with a maximum match of up to 3% of the employee’s eligible pay. Participant are also due a nonmatching contribution. A nonmatching contribution of 5% of eligible pay is provided to employees who are not eligible for pension plan accruals. Until September 30, 2022, employees who were eligible for pension plan accruals received a nonmatching contribution of 4% of eligible pay. Pension accruals ceased for this group September 30, 2022 and effective October 1, 2022, their nonmatching contribution increased to 5% of eligible pay. Employer contributions expense related to the Battelle Columbus employees in this plan amounted to \$29,118 and \$25,016 in 2022 and 2021, respectively.

The Battelle Employees’ Savings Plan for the Battelle Pacific Northwest Division (the “Battelle PNNL”) prescribes that employer-matching contributions are made at 50% of each individual employee’s contribution, with a maximum match of up to 3.5% of the employee’s salary, subject to other limitations specified in the plan. Employer contribution expense related to the Battelle PNNL employees in the plan amounted to \$12,737 and \$11,622 in 2022 and 2021, respectively.

Triad maintains two 401(k) plans, the Triad 401(k) Savings Plan and the Triad 401(k) Retirement Plan, covering all employees who meet the eligibility requirements. Triad matches 100% of each participant’s contributions up to 6% of their eligible compensation. The Company also performs an annual non-elective contribution in each participant’s 401(k) plan based on years of service with the Company and eligible compensation. Employer contribution expense related to the two Triad 401(k) plans amounted to \$93,638 and \$83,406 as of September 30, 2022 and 2021, respectively.

Defined Benefit Pension and Retiree Medical Plans—Battelle has defined benefit pension plans that cover many salaried and eligible hourly employees of its corporate operations. The plans provide defined benefits either based on years of service and average salary of the highest five consecutive years or a 1% cash balance arrangement.

Battelle also has a postretirement medical plan (the “Postretirement Plan”) covering the employees of its corporate operations, who were hired prior to July 1, 2005. An account-based postretirement medical plan with a fixed annual contribution was implemented on January 1, 2013. The accounting for the Postretirement Plan is consistent with Battelle’s expressed intent to limit increases to the employer subsidy to no more than 5% per year.

Changes to the Retiree Medical Plan—During 2019, the plan was closed to new retirees effective June 1, 2019, and further amended to eliminate benefits for healthy retirees effective December 31, 2020. Benefits under this plan will continue to be available to certain disabled retirees currently benefiting under this plan.

Changes to the Pension Plans—During 2015, Battelle announced that the pension plan would be frozen for further benefit accruals for all the Battelle Columbus location employees whose combination of age, plus years of pension vesting service, is less than 60 as of June 30, 2015. Beginning July 1, 2015, no new participants from the Battelle Columbus location would enter the pension plan.

During 2017, Battelle approved a spin-off of the 2017 Plan from the Battelle Plan. The new plan included only participants with benefits that are “frozen” such that participants in the 2017 Plan will not accrue further benefits under the plan. Any active plan participants in the 2017 Plan had benefits frozen as of either June 30, 2015 (see discussion above), or June 30, 2011 (see discussion above). The 2017 Plan also includes some terminated former employees and retirees that were previously in the aforementioned national laboratory and Battelle participants. For purposes of the footnote presentation, these plans are presented in the aggregate.

During 2018, the Company restructuring triggered a curtailment event for the BMI Plan. The curtailment event resulted in a one-time gain of \$1,002 recognized in Net periodic pension and postretirement benefits costs, less service costs within the Company’s Consolidated Statements of Operations.

During 2022, the former Battelle Memorial Institute Plan was merged into the 2017 Employees Pension Plan of Battelle Memorial as of June 30, 2022. Effective September 30, 2022, the 2017 Employees Pension Plan of Battelle Memorial was curtailed, which resulted in a curtailment gain of \$9,452 (recognized in Net periodic pension and postretirement benefits costs, less service costs within the Company’s Consolidated Statements of Operations).

The plans' benefit obligations and fair value of plan assets as of the measurement date of September 30, 2022, 2021, and 2020, are noted in the table below. The values reflect the changes due to the aforementioned plan amendments, curtailments, and mergers.

Change in Projected Benefit Obligation	Battelle Plan and SERP Postretirement 2017 Plan		
Projected obligation—September 30, 2020	\$ 797,977	\$ 1,485	\$ 346,690
Service cost	3,788	-	1,070
Interest cost	23,488	33	9,342
Actuarial loss (gain)	(11,287)	(460)	(11,547)
Plan settlements	(26,481)	-	-
Plan amendments	-	-	-
Benefit payments	<u>(29,680)</u>	<u>(759)</u>	<u>(29,413)</u>
Projected obligation—September 30, 2021	757,805	299	316,142
Service cost	2,579	-	1,124
Interest cost	16,323	4	16,334
Actuarial loss (gain)	(124,720)	(31)	(107,707)
Plan settlements	-	-	-
Plan combinations	(612,799)	-	612,799
Benefit payments	<u>(37,720)</u>	<u>(49)</u>	<u>(42,324)</u>
Projected obligation—September 30, 2022	1,468	223	796,368
Change in Fair Value of Plan Assets			
Fair value of plan assets—September 30, 2020	\$ 620,430	\$ 3,006	\$ 437,728
Actual return on plan assets	(2,864)	-	(538)
Employer contributions	75,181	-	-
Plan settlements	(26,481)	-	-
Benefit paid and expected expenses—benefit payments	<u>(29,679)</u>	<u>(759)</u>	<u>(29,413)</u>
Fair value of plan assets—September 30, 2021	636,587	2,247	407,777
Actual return on plan assets	(67,629)	8	(80,021)
Employer contributions	-	-	-
Plan combinations	(531,412)	-	531,412
Benefit paid and expected expenses—benefit payments	<u>(37,546)</u>	<u>(49)</u>	<u>(42,324)</u>
Fair value of plan assets—September 30, 2022	<u>\$ -</u>	<u>\$ 2,206</u>	<u>\$ 816,844</u>
Funded status (deficit) surplus—September 30, 2021	<u>\$ (121,218)</u>	<u>\$ 1,948</u>	<u>\$ 91,635</u>
Funded status (deficit) surplus—September 30, 2022	<u>\$ (1,468)</u>	<u>\$ 1,983</u>	<u>\$ 20,476</u>

Amounts recognized in the consolidated balance sheets as of September 30, consisted of the following:

	2022		2021	
	Pension	Postretirement	Pension	Postretirement
Noncurrent assets—net amount recognized	\$ 20,476	\$ 1,983	\$ 91,635	\$ 1,948
Noncurrent liabilities—net amount recognized	\$ (1,468)	\$ -	\$ (121,218)	\$ -

The funded status for each of Battelle’s pension and postretirement plans improved in fiscal year 2022, primarily driven by significant return on assets, offset partially by the reduction of discount rates which led to increased benefit obligations.

Amounts recognized in accumulated other comprehensive income as of September 30, consisted of the following:

	2022			2021		
	Battelle Plan and SERP	Postretirement	2017 Plan	Battelle Plan and SERP	Postretirement	2017 Plan
Accumulated (loss) gain	\$ 13	\$ 2,553	\$ (185,479)	\$ (175,071)	\$ 2,676	\$ (58,236)
Accumulated prior-year service credit	\$ -	\$ 22,605	\$ -	\$ 11,795	\$ 23,975	\$ 312

Net periodic cost as of September 30, consisted of the following:

	Battelle Plan and SERP	Postretirement	2017 Plan	Battelle Plan and SERP	Postretirement	2017 Plan
Service cost	\$ 2,579	\$ -	\$ 1,124	\$ 3,788	\$ -	\$ 1,070
Interest cost	16,323	4	16,334	23,488	34	9,342
Expected return on plan assets	(26,041)	(39)	(28,245)	(32,314)	(45)	(23,104)
Amortization of prior service cost	(1,757)	(1,370)	(898)	(3,895)	(1,370)	(1,185)
Curtailment gain	-	-	(9,452)	-	-	-
Settlement loss	-	-	-	6,135	-	-
Amortization of net actuarial (gain) / loss	11,437	(122)	5,913	13,591	(161)	329
Net periodic benefit cost	\$ 2,541	\$ (1,527)	\$ (15,224)	\$ 10,793	\$ (1,542)	\$ (13,548)

Pension and other postretirement expenses of \$431,315 and \$441,899 for the years ended September 30, 2022 and 2021, respectively, related to the government-owned, contractor-operated labs were recorded in cost of operations. The pension expenses related to the government-owned, contractor operated labs are recorded on a cash contribution basis as the plans represent multi-employer plans. The pension liabilities associated with these plans contractually are not those of Battelle or its subsidiaries.

Assumptions—Weighted-average assumptions used to determine benefit obligations as of September 30, were as follows:

	2022		2021	
	Pension	Postretirement	Pension	Postretirement
Discount rate	4.84% - 5.63%	4.79%	2.33% - 2.99%	1.48%
Rate of compensation increase (BMI Plan only)	3%	N/A	3%	N/A

Weighted-average assumptions used to determine net periodic benefit cost for the years ended September 30, were as follows:

	2022		2021	
	Pension	Postretirement	Pension	Postretirement
Discount rate	2.33% - 2.99%	1.48%	2.25% - 3.06%	3.19%
Expected return on plan assets	5.75%	1.75%	5.50%	1.75%
Rate of compensation increase (BMI Plan only)	3.00%	N/A	3.00%	N/A

The expected long-term rate of return was developed by considering the target asset allocation, long-term historical market returns, and long-term projected market return.

The health care cost trend rates represent the rate of increase in employer claim payments. Battelle's postretirement benefit costs are capped at a 5% annual increase. Future medical cost trend increases, which was assumed to be above the 5% cap, therefore, will have no material effect on plan liabilities.

In December 2003, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the "Act") became law in the United States. The Act introduced a prescription drug benefit under Medicare, as well as a federal subsidy to sponsors of retiree health care benefit plans that provide a benefit that is at least actuarially equivalent to the Medicare benefit. The postretirement benefit values contained above do not reflect any amount associated with any subsidy provided by the Act. Any drug benefit resulting from this Act will be used to decrease retiree contributions and not the employer subsidy, thereby causing no net effect of the Act on the plan.

Plan Assets—Battelle's pension plans and postretirement plan weighted-average asset allocations as of September 30, by asset category, were as follows:

Asset Category	2022				2021			
	Pension		Postretirement		Pension		Postretirement	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Equity securities	25 %	7 %	0%	0%	65 %	38 %	0%	0%
Debt securities	75 %	49 %	0%	0%	35 %	36 %	0%	0%
Cash	0%	16 %	100%	100%	0%	8 %	100%	100%
Real estate/other	0%	28 %	0%	0%	0%	18 %	0%	0%

The investment plan strives to optimize the availability of funds in relation to the long-term liabilities on the pension and postretirement plans. A long-term investment horizon enables the funds to tolerate the risk of somewhat volatile investment returns in the short run, with the expectation of higher returns in the long run. The funds are diversified across several asset classes and many securities to reduce risk. Current income is not a key goal of the plans, although current cash requirements related to benefit responsiveness are considered in the investment process. Derivatives are permitted only for hedging and transactional efficiency.

As required by ASC 820, financial assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of fair value assets and their placement within the fair value hierarchy levels, which are outlined in Note 5—Fair Value of Financial Instruments.

The pension plan assets are part of a master trust. As of September 30, 2022, the plan assets associated with the consolidated financial statements consisted of approximately 31.7% or \$816,844 of the master trust. The pension's assets, set forth by level within the fair value hierarchy, as of September 30, 2022, are as follows:

	Active Markets for Identical Assets (Level 1)	Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
Common stock	\$ 8,788	\$ -	\$ -	\$ 8,788
Government bonds	-	313,716	-	313,716
Private equity funds	-	-	806	806
Real estate	-	-	1,371	1,371
Dividend and interest receivable	<u>291</u>	<u>1,084</u>	<u>-</u>	<u>1,375</u>
Total investment ⁽¹⁾	<u>\$ 9,079</u>	<u>\$ 314,800</u>	<u>\$ 2,177</u>	<u>\$ 326,056</u>

⁽¹⁾ Not included in this table is \$134,321 of cash as well as the assets valued at net asset value per share as noted in the following table.

The pension plan assets are part of a master trust. As of September 30, 2021, the plan assets associated with the consolidated financial statements consisted of approximately 32.9% or \$1,044,364 of the master trust. The pension's assets, set forth by level within the fair value hierarchy, as of September 30, 2021, are as follows:

	Active Markets for Identical Assets (Level 1)	Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
Common stock	\$ 235,001	\$ 20	\$ 3,956	\$ 238,977
Government bonds	-	392,761	-	392,761
Commingled funds	14	5,960	-	5,974
Private equity funds	-	17,032	3,878	20,910
Real estate	-	235	172	407
Huntington National Bank benefit	-	-	-	-
Dividend and interest receivable	<u>331</u>	<u>1,034</u>	<u>-</u>	<u>1,365</u>
Total investment ⁽¹⁾	<u>\$ 235,346</u>	<u>\$ 417,042</u>	<u>\$ 8,006</u>	<u>\$ 660,394</u>

⁽¹⁾ Not included in this table is \$64,217 of cash as well as the assets valued at net asset value per share as noted in the following table.

As of September 30, the following plan financial assets measured at net asset value per share were categorized as follows:

	Fair Value	
	2022	2021
Funds—common stock ⁽¹⁾	\$ 19,949	\$ 92,740
Funds—securitized credit ⁽²⁾	85,223	38,938
Real estate ⁽³⁾	51,071	44,134
Private equity ⁽⁴⁾	<u>200,224</u>	<u>143,941</u>
Total	<u>\$ 356,467</u>	<u>\$ 319,753</u>

- (1) Funds—common stock—This class includes publicly traded equity, primarily stocks. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.
- (2) Securitized credit—This class includes investments in commercial mortgage-backed securities, residential mortgage-backed securities, and collateralized loan obligations. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.
- (3) Real estate—This class includes several real estate funds that invest primarily in various types of real estate. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.
- (4) Private equity—This class includes limited partnership investments. The fair values of the investments in this class have been derived by using the net asset value per share of the investments.

During Fiscal Year 2022 there were Level 3 asset purchases of \$(632) and net transfers out of Level 3 assets of \$3,186.

The postretirement plan's assets, set forth by level within the fair value hierarchy, as of September 30, are as follows:

	Net Asset Value	
	2022	2021
Funds—short-term investment	\$ 2,206	\$ 2,248

Contributions—In 2023, Battelle expects to contribute \$0 to its pension and postretirement benefit plans. In 1999, the plans were amended to pay certain retiree medical claims from pension plan assets through a 401(h) account as permitted by Section 420 of the Internal Revenue Code.

Estimated Future Benefit Payments—The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

Years Ending September 30,	Pension & SERP	Postretirement	Total
2023	\$ 83,634	\$ 61	\$ 83,695
2024	70,084	44	70,128
2025	67,742	37	67,779
2026	65,902	36	65,938
2027	63,935	25	63,960
2028 - 2032	<u>298,884</u>	<u>48</u>	<u>298,932</u>
Total	<u>\$ 650,181</u>	<u>\$ 251</u>	<u>\$ 650,432</u>

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Battelle is involved in various lawsuits, claims, and administrative proceedings arising in the normal course of business. Management is of the opinion that any liability or loss associated with such matters, either individually or in aggregate, will not have a material adverse effect on Battelle's operations and liquidity. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.

Obligation under the Will—Battelle, pursuant to the Will and related subsequently issued agreements, is required, among other things, to distribute to qualified recipients a portion of its net income each year. Battelle is required to provide an annual distribution in the amount of the greater of 20% of Battelle's annual net income (excluding unrealized gains and losses on available for sale investments), or \$3,000 to qualified charitable causes. Of those distributed, at least 62% of the total annual distribution to qualified charitable causes shall be made in central Ohio for the benefit of central Ohio. Battelle's total obligation, as determined under the above formula for distribution to qualified recipients, was \$27,455 and \$27,400 for the years ended September 30, 2022 and 2021, respectively.

As of September 30, 2022, and 2021, Battelle is compliant with the distribution obligation.

NOTE 13 – CASH FLOWS – SUPPLEMENTAL INFORMATION

(In thousands)	Years Ended September 30,	
	2022	2021
Supplemental Disclosures:		
Income taxes, net of refunds	\$ (2,278)	\$ (904)
Interest paid, net of amounts capitalized	(7,608)	(10,496)
Noncash Investing and Financing Activities:		
Capital additions in accounts payable	3,731	685
Investments mark-to-market adjustments	27,545	7,186
Amounts reclassified from Other Comprehensive Income for Pension and Postretirement Benefits	34,241	22,114
Balance sheet account reclassification resulting from pension plan merger	127,268	-
Pending investment sales	1,989	2,242
Pending investment purchases	758	1,197
Asset transferred to held for sale	1,529	1,000
Reclassification of Debt Payable from long term to short term	-	40,000
Reclassification of available-for-sale securities from long-term to short-term	2,285	287
Exchange of noncash assets/liabilities for AmplifyBio investment	967	35,025
Adoption of ASC 842	-	28,984
Credit unbilled	2,086	-
Direct expense invoice accrual	10,000	-

NOTE 14 – RELATED PARTY TRANSACTIONS

For the years ended September 30 common or related parties balances were as follows:

	Years ended September 30,	
	2022	2021
Sales	\$ 2,924	\$ 1,921
Purchases	2,739	1,830
Accounts Receivable balance	340	1,613
Officer Loans	12,734	8,047

Sales and Purchases—Battelle sells and/or purchases certain services to and from other companies related to us through common or affiliated ownership and/or board of directors and/or management relationships.

Officer Loans—The Board of Directors of Battelle approved and adopted the Battelle Capital Accumulation Plan (“BCAP”), effective July 1, 2019. The program constitutes a loan regime split-dollar life insurance program, under which participants will purchase and own life insurance policies, subject to collateral assignment of certain policy proceeds to ensure the repayment, with interest, of the funds advanced for their benefit. Battelle is responsible for paying directly to the insurer all planned periodic premiums during the premium payment period while the participating employee is actively employed by Battelle. Premiums and certain associated fees paid by Battelle to the participant’s policies under BCAP are recorded as related party loans receivable on the Company’s Consolidated Balance Sheets.

NOTE 15 – SUBSEQUENT EVENT

The Company has performed an evaluation of subsequent events through November 30, 2022, which is the date the Financial Statements were available to be issued. The Company determined no additional disclosure is necessary.

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

Agency Code	CFDA	R&D	Federal Agency	Major Sub Agency/Program Title	Total Expenditures	Subcontracted Dollars	Contract Ref.
I. Direct Funding							
10	310	Yes	Department of Agriculture	National Institute of Food and Agriculture - AFRI	\$ 96,232	\$ 56,700	2021-67037-34847
					96,232	56,700	
11	609	Yes	Department of Commerce	National Institute of Standards, Measurement and Engineering Research	44,854	-	70NANB20H213T
					44,854	-	
12	300	Yes	Department of Defense	Navy - Basic and Applied Scientific Research	520,567	-	N00014-18-1-2887
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	9,624,786	8,948,133	W911SR-15-2-0001
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	332,648	-	W911SR-15-2-0001 DO 0004
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	18,033	-	W911SR-15-2-0001:0000512359
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	166,303	-	W911SR-15-2-0001/0010
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	116,042	-	W911SR-15-2-0001/0007
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	82,744	-	W911SR-15-2-0001/0002
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	585,001	-	W911SR-15-2-0001/0005
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	56,220	-	W911SR-15-2-0001/0011
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	92,685	-	W911SR-15-2-0001/0009
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	13,327	-	W911SR-15-2-0001/0003
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	101,837	-	W911SR-15-2-0001 / W911SR19F0059
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	150,187	-	W911SR-15-2-0001/W911SR20F0004 DO 0014
12	630	Yes	Department of Defense	Army - Basic, Applied, and Advanced Research in Science/Eng	66,467	-	W911SR1520001 / W911SR20F0037
12	800	Yes	Department of Defense	Air Force	679,216	-	FA8650-19-2-6985
12	420	Yes	Department of Defense	Army - Military Medical Research and Development	49,091	-	W81XWH-22-1-0594
12	RD	Yes	Department of Defense	Air Force	556,489	209,576	FA865020D5703
12	RD	Yes	Department of Defense	Air Force	418,957	-	22F0012
12	RD	Yes	Department of Defense	Air Force	291,155	-	FA8650-22-C-6296
12	RD	Yes	Department of Defense	Air Force	37,417	-	FA70222D0003
12	RD	Yes	Department of Defense	Air Force	166,216	-	FA9453-22-C-0115
12	RD	Yes	Department of Defense	Air Force	60,258	-	OPP217035 Task Order 2
12	RD	Yes	Department of Defense	Air Force	36,483	-	GS00Q14OADU402
12	RD	Yes	Department of Defense	Air Force	26,087	7,933	FA8504-15-C0002
12	RD	Yes	Department of Defense	Air Force	1,586	-	FA8075-14-D-0003 DO 0009
12	RD	Yes	Department of Defense	Air Force	2,203,198	179,355	FA8075-14-D-0015 / TO 004
12	RD	Yes	Department of Defense	Air Force	1,965,671	280,133	15-D-1953
12	RD	Yes	Department of Defense	Air Force	1,536,374	334,281	FA8224-18-C-0003
12	RD	Yes	Department of Defense	Air Force	7,505,945	2,925,710	GS00Q14OADU402 / 47QFSA18F0003
12	RD	Yes	Department of Defense	Air Force	6,785,208	1,022,991	GS00Q14OADU402 / FA8051-19-F-A020
12	RD	Yes	Department of Defense	Air Force	3,097,587	12,782	FA865015D1953 / FA8650-20-F-1134
12	RD	Yes	Department of Defense	Air Force	2,525,960	1,859,768	FA8650-20-D-5703
12	RD	Yes	Department of Defense	Air Force	(684)	-	47QTCK18D0012
12	RD	Yes	Department of Defense	Air Force	9,462	-	FA702217D0008 / FA702221F0005
12	RD	Yes	Department of Defense	Air Force	3,626,742	587,516	FA807518D0005/ DO FA807521F0065
12	RD	Yes	Department of Defense	Air Force	407,334	-	FA7022-17-D-0008
12	RD	Yes	Department of Defense	Air Force	1,957,515	1,260,345	FA865020D5703 / FA8650-21-F-5702
12	RD	Yes	Department of Defense	Air Force	9,918,257	2,273,595	FA807518D0005-FA807521F0082 (P1-21-2267)
12	RD	Yes	Department of Defense	Army	33,484	-	W912HQ22C0061
12	RD	Yes	Department of Defense	Army	35,925	-	Task order 006; OPP221785
12	RD	Yes	Department of Defense	Army	54,531	10,202	FA8075-14-D-0015 DO 2T02
12	RD	Yes	Department of Defense	Army	11,036	5,629	FA8075-14-D0015 DO 2T01
12	RD	Yes	Department of Defense	Army	(444)	-	GS00Q14OADU102
12	RD	Yes	Department of Defense	Army	981	-	W911NF-15-D-0002

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

12	RD	Yes	Department of Defense	Army	(35,037)	-	W911NF-16-F-0023
12	RD	Yes	Department of Defense	Army	494,177	353,727	W911NF-15-D-0002-0003
12	RD	Yes	Department of Defense	Army	605,536	130,470	FA8075-14-D0015 DO 2T03
12	RD	Yes	Department of Defense	Army	2,467,846	1,223,701	FA8075-14-D-0003-FA807517F1402
12	RD	Yes	Department of Defense	Army	43,420	16,540	W911NF-17-C-0052
12	RD	Yes	Department of Defense	Army	1,078	-	W911NF-15-D-0002-0007
12	RD	Yes	Department of Defense	Army	2,240,541	208,111	FA8075-14-D-0015 / FA807518F1326
12	RD	Yes	Department of Defense	Army	121,491	121,491	GS00Q14OADU102/ORDER 47QFRA18F0071/ACT A21911136/TASK ORDER ID08180041
12	RD	Yes	Department of Defense	Army	383,406	-	W911NF-19-C-0090
12	RD	Yes	Department of Defense	Army	8,222,601	2,568,182	FA8075-14-D-0003 / DO FA807519FA020
12	RD	Yes	Department of Defense	Army	337,940	42,054	W912HQ20C0048
12	RD	Yes	Department of Defense	Army	10,145,630	5,235,741	GS00Q14OADU402 / W9132V19F0005
12	RD	Yes	Department of Defense	Army	1,778,685	22,896	FA8075-18-D-0016
12	RD	Yes	Department of Defense	Army	1,139,285	620,739	FA807518D0005/FA807520F0059
12	RD	Yes	Department of Defense	Army	6,477,640	72,935	FA8075-18-D-0005 / DO FA807520F0064
12	RD	Yes	Department of Defense	Army	687,531	209,752	W15P7T-19-D-0156
12	RD	Yes	Department of Defense	Army	271,074	56,400	FA807518D0016 FA807521F0058 (P3-20-2188)
12	RD	Yes	Department of Defense	Central Command	561,291	272,206	GS00Q14OADU102/ORDER 47QFSA18F0065/ACT A21917266/TASK ORDER ID04180042
12	RD	Yes	Department of Defense	Chief Information Officer	1,476,715	-	FA807522F0056 FA807518D0005
12	RD	Yes	Department of Defense	Classified	2,536,645	-	21C0194
12	RD	Yes	Department of Defense	Classified	351,276	-	17G002
12	RD	Yes	Department of Defense	Classified	2,557	-	22040600002
12	RD	Yes	Department of Defense	Classified	252,848	-	19D0000632
12	RD	Yes	Department of Defense	Classified	1,983	-	21D0003
12	RD	Yes	Department of Defense	Classified	65,544	-	XXXXXX-21-F-0001
12	RD	Yes	Department of Defense	Classified	2,866	-	B15-2015175G001
12	RD	Yes	Department of Defense	Classified	5,575,190	-	16-16152G003
12	RD	Yes	Department of Defense	Classified	600,505	-	17032100007
12	RD	Yes	Department of Defense	Classified	308,421	104,078	244G002
12	RD	Yes	Department of Defense	Classified	32,430	-	A000392690
12	RD	Yes	Department of Defense	Classified	33,343	-	244G002-005
12	RD	Yes	Department of Defense	Classified	19,385	-	244G002-004
12	RD	Yes	Department of Defense	Classified	9,556,889	4,511	18C5090
12	RD	Yes	Department of Defense	Classified	4,767	-	1200-D-0001759
12	RD	Yes	Department of Defense	Classified	969,671	-	117G002
12	RD	Yes	Department of Defense	Classified	61,948	50,835	2015244G002-6
12	RD	Yes	Department of Defense	Classified	359,500	-	117G002-003
12	RD	Yes	Department of Defense	Classified	182,583	-	117G002-005
12	RD	Yes	Department of Defense	Classified	62,972	-	CB-AT-4853
12	RD	Yes	Department of Defense	Classified	2,258,787	-	15F06719D0000632 / 15F06719F0002323
12	RD	Yes	Department of Defense	Classified	1,408,949	-	15F06719D0000632 / 15F06719F0002278
12	RD	Yes	Department of Defense	Classified	258,957	-	19203G401
12	RD	Yes	Department of Defense	Classified	1,966	-	19203G401-002
12	RD	Yes	Department of Defense	Classified	2,092	-	19203G401-003
12	RD	Yes	Department of Defense	Classified	4,561	-	19203G401-004
12	RD	Yes	Department of Defense	Classified	5,049	-	19203G401-005
12	RD	Yes	Department of Defense	Classified	839	-	19203G401-006
12	RD	Yes	Department of Defense	Classified	981,757	-	60900001
12	RD	Yes	Department of Defense	Classified	2,490	-	19203G401-007
12	RD	Yes	Department of Defense	Classified	7,331	-	19203G401-008
12	RD	Yes	Department of Defense	Classified	403,756	230,073	15-D-0001 - 20F0046
12	RD	Yes	Department of Defense	Classified	264,750	-	117G002-006
12	RD	Yes	Department of Defense	Classified	1,180,508	42,385	17G002-007
12	RD	Yes	Department of Defense	Classified	474,209	64,310	117G002-008
12	RD	Yes	Department of Defense	Classified	167,759	-	FA8750-18-D-0001

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

12	RD	Yes	Department of Defense	Classified	978,373	-	203G401-009
12	RD	Yes	Department of Defense	Classified	2,629,855	-	ATP Crimson II
12	RD	Yes	Department of Defense	Classified	678,133	-	17G002-010
12	RD	Yes	Department of Defense	Classified	736,966	27,090	117G002-009
12	RD	Yes	Department of Defense	Classified	27,658	-	21-1195G003
12	RD	Yes	Department of Defense	Classified	11,023,993	2,008,312	21-D-0003
12	RD	Yes	Department of Defense	Defense Advanced Research Projects Agency	5,123,626	98,874	HR001119C0019
12	RD	Yes	Department of Defense	Defense Advanced Research Projects Agency	957,879	455,646	W911NF19C0041
12	RD	Yes	Department of Defense	Defense Advanced Research Projects Agency	5,259,456	513,341	HR001120C0118
12	RD	Yes	Department of Defense	Defense Advanced Research Projects Agency	5,921,855	1,369,715	HR001121C0027
12	RD	Yes	Department of Defense	Defense Advanced Research Projects Agency	2,652,391	1,145,000	HR001121C0029
12	RD	Yes	Department of Defense	Defense Intelligence Agency	818,277	818,277	GSA-00F-084CA / D17PD00383 / SIN 874-4
12	RD	Yes	Department of Defense	Defense Technical Information Center	93	-	FA807518D0005 (Pool 1) / FA807
12	RD	Yes	Department of Defense	Defense Threat Reduction Agency	76,885	57,083	HDTRA120C0011
12	RD	Yes	Department of Defense	Environmental Security Technology	225,724	9,859	W912HQ19C0005
12	RD	Yes	Department of Defense	Joint Program Executive Office	70,470	53,727	FA8075-14-D-0003-0005
12	RD	Yes	Department of Defense	Joint Program Executive Office	1,536,268	782,497	W911QY-18-F-0701
12	RD	Yes	Department of Defense	Joint Program Office	1,631,703	797,509	FA807522F0014
12	RD	Yes	Department of Defense	Joint Program Office	(126,930)	-	GS-00Q14OADU402, W911QY-16-F-0074
12	RD	Yes	Department of Defense	Joint Program Office	608,241	-	FA8075-14-D-0003 DO 0011
12	RD	Yes	Department of Defense	Joint Program Office	998,127	793,499	FA8075-14-D-0003/FA807517F1416
12	RD	Yes	Department of Defense	Joint Program Office	3,356,036	919,256	GS00Q14OADU402/ /POOL 4/ W911QY-18-F-0007
12	RD	Yes	Department of Defense	Joint Program Office	21,059,164	9,417,298	FA8075-18-D-0016-FA807521F0011
12	RD	Yes	Department of Defense	Joint Program Office	2,293,992	9,512	FA807518D0016-FA807521F0057
12	RD	Yes	Department of Defense	Joint Project Manager for Medical Countermeasures	291,598	-	FA807522F0023
12	RD	Yes	Department of Defense	National Guard Bureau	84,873	-	FA8075-14-D-0003-FA807517F1176
12	RD	Yes	Department of Defense	National Guard Bureau	4,225,031	-	Contract GS00Q14OADU402 - Order 47QFSA20F0081/ Task Order ID04200016
12	RD	Yes	Department of Defense	Navy	152,529	-	N3943016D1802 / N3943022F4305
12	RD	Yes	Department of Defense	Navy	282,604	-	N39430-16-D-1802/ N3943022F4304
12	RD	Yes	Department of Defense	Navy	39,939	-	N00014-21-C-2004
12	RD	Yes	Department of Defense	Navy	2,131	-	N62583-11-D-0515 - DO 0047
12	RD	Yes	Department of Defense	Navy	1,004	-	N62583-11-D-0515 / DO 0048
12	RD	Yes	Department of Defense	Navy	457	-	N62583-11-D-0515 / DO 0053
12	RD	Yes	Department of Defense	Navy	13,193	-	N62583-11-D-0515 - DO 0055
12	RD	Yes	Department of Defense	Navy	111	-	N62583-11-D-0515 - DO 0080
12	RD	Yes	Department of Defense	Navy	976	520	N62583-11-D-0515
12	RD	Yes	Department of Defense	Navy	1,974	-	N00189-15-C-Z076
12	RD	Yes	Department of Defense	Navy	117,158	29,707	N39430-16-D-1802 / 0003
12	RD	Yes	Department of Defense	Navy	651,720	1,156	N39430-16-D-1802 / 0008
12	RD	Yes	Department of Defense	Navy	140,946	-	FA8075-16-D-0002 / FA807517F1368
12	RD	Yes	Department of Defense	Navy	16,052	6,413	N39430-16-D-1802 - 0012
12	RD	Yes	Department of Defense	Navy	933	-	N39430-16-D-1802 / N3943017F4025
12	RD	Yes	Department of Defense	Navy	1,174,962	193,618	N39430-16-D-1802 / 0009
12	RD	Yes	Department of Defense	Navy	101,291	53,477	N39430-16-D-1802 / N3943017F4038
12	RD	Yes	Department of Defense	Navy	1,241	-	N39430-16-D-1802 / 0015
12	RD	Yes	Department of Defense	Navy	57	-	N39430-16-D-1802 N3943017F4048
12	RD	Yes	Department of Defense	Navy	354,935	1,260	N39430-16-D-1802 / N3943017F4090
12	RD	Yes	Department of Defense	Navy	193	-	N39430-16-D-1802 N3943017F4080
12	RD	Yes	Department of Defense	Navy	91,361	-	N39430-16-D-1802 / N3943017F4109
12	RD	Yes	Department of Defense	Navy	1,570,188	792,656	N39430-16-D-1802 / N3943017F4142
12	RD	Yes	Department of Defense	Navy	21,655	15,842	N39430-16-D-1802 / N3943017F4111
12	RD	Yes	Department of Defense	Navy	149,538	9,700	N39430-16-D-1802 / N3943017F4141
12	RD	Yes	Department of Defense	Navy	5,333	3,234	N6833518C0179
12	RD	Yes	Department of Defense	Navy	295,055	288	N3943016D1802 / N3943018F4147
12	RD	Yes	Department of Defense	Navy	3,219,694	2,476,907	N6600119C4019

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

12	RD	Yes	Department of Defense	Navy	408,938	223,939	N3943016D1802 / N3943018F4151
12	RD	Yes	Department of Defense	Navy	72,899	-	N3943016D1802 / N3943018F4328
12	RD	Yes	Department of Defense	Navy	62,917	51,172	W911NF-17-D-0011- DO W911NF18F
12	RD	Yes	Department of Defense	Navy	363,895	131	N3943016D1802 / N3943018F4354
12	RD	Yes	Department of Defense	Navy	844,008	77,727	N3943016D1802 / N3943018F4359
12	RD	Yes	Department of Defense	Navy	23,825	-	N3943016D1802 / N3943018F4355
12	RD	Yes	Department of Defense	Navy	175,525	-	N3943016D1802 / N3943018F4387
12	RD	Yes	Department of Defense	Navy	98,938	1,950	N3943016D1802 / N3943018F4396
12	RD	Yes	Department of Defense	Navy	3,650	-	N3943016D1802 / N3943018F4410
12	RD	Yes	Department of Defense	Navy	133,696	1,050	N3943016D1802 / N3943018F4398
12	RD	Yes	Department of Defense	Navy	60,112	46,455	N3943016D1802 - N3943018F4379
12	RD	Yes	Department of Defense	Navy	59,148	-	N3943016D1802 / N4008019F4588
12	RD	Yes	Department of Defense	Navy	4,010	-	N3943016D1802 / N3943019F4083
12	RD	Yes	Department of Defense	Navy	1,862,930	765,996	N3943016D1802 / N6247319F4965
12	RD	Yes	Department of Defense	Navy	454,144	105,294	N3943016D1802 / N3943019F4131
12	RD	Yes	Department of Defense	Navy	169,306	68,139	N3943016D1802 / N6247319F5192
12	RD	Yes	Department of Defense	Navy	189,908	-	N3943016D1802 / N3943019F4121
12	RD	Yes	Department of Defense	Navy	8,736	2,754	N3943016D1802 / N6247319F5227
12	RD	Yes	Department of Defense	Navy	157,851	96,475	N3943016D1802 / N6247319F5442
12	RD	Yes	Department of Defense	Navy	29,278	14,754	N3943016D1802 / N3943020F4066
12	RD	Yes	Department of Defense	Navy	1,551	-	N3943016D1802 / N3943020F4061
12	RD	Yes	Department of Defense	Navy	795,659	-	N4175620C4417
12	RD	Yes	Department of Defense	Navy	374,313	71,351	N3943016D1802 / N3943020F4098
12	RD	Yes	Department of Defense	Navy	134,753	20,939	N3943016D1802 / N3943020F4146
12	RD	Yes	Department of Defense	Navy	311,564	43,320	N3943016D1802 / N3943020F4182
12	RD	Yes	Department of Defense	Navy	51,413	-	N3943016D1802 / N4425520F4307
12	RD	Yes	Department of Defense	Navy	47,251	-	N3943016D1802 / N4425520F4306
12	RD	Yes	Department of Defense	Navy	113,473	61,582	N3943016D1802 / N6247320F5085
12	RD	Yes	Department of Defense	Navy	447,242	180,869	N3943016D1802 / N3943020F4183
12	RD	Yes	Department of Defense	Navy	353,992	-	N0018920CZ035
12	RD	Yes	Department of Defense	Navy	66	-	N3943016D1802 / N4425520F4405
12	RD	Yes	Department of Defense	Navy	155,664	-	N3943016D1802 / N6945020F0491
12	RD	Yes	Department of Defense	Navy	126,013	24,750	N3943016D1802 / N3943021F4030
12	RD	Yes	Department of Defense	Navy	856,755	6,638	N3943016D1802 / N3943021F4029
12	RD	Yes	Department of Defense	Navy	547,956	203,332	N3943016D1802 / N6247321F4495
12	RD	Yes	Department of Defense	Navy	1,028,172	343,021	N3943016D1802 / N6247321F4520
12	RD	Yes	Department of Defense	Navy	1,431,651	355,491	N3943016D1802 / N6945021F0189
12	RD	Yes	Department of Defense	Navy	117,182	77,483	N3943016D1802 / N3943021F4078
12	RD	Yes	Department of Defense	Navy	791,161	130,552	N3943016D1802 / N6247321F4786
12	RD	Yes	Department of Defense	Navy	348,427	107,891	N3943016D1802 / N3943021F4081
12	RD	Yes	Department of Defense	Navy	161,100	-	N3943016D1802 / N3943021F4085
12	RD	Yes	Department of Defense	Navy	57,170	-	N3943016D1802 / N3943021F4088
12	RD	Yes	Department of Defense	Navy	122,787	-	N3943016D1802 / N6945021F0306
12	RD	Yes	Department of Defense	Navy	248,101	52,161	N3943016D1802 / N4425521F4224
12	RD	Yes	Department of Defense	Navy	835,402	410,875	N3943016D1802 / N4425521F4225
12	RD	Yes	Department of Defense	Navy	260,831	164,088	N3943016D1802 / N4425521F4226
12	RD	Yes	Department of Defense	Navy	318,005	170,711	N3943016D1802 / N3943021F4134
12	RD	Yes	Department of Defense	Navy	1,291,380	363,947	N3943016D1802 / N3943021F4179
12	RD	Yes	Department of Defense	Special Operations Command	145,194	-	H92222-16-D-0043
12	RD	Yes	Department of Defense	Special Operations Command	451,951	-	H9240322F0014
12	RD	Yes	Department of Defense	Special Operations Command	55,907	-	47QFSA20D0001
12	RD	Yes	Department of Defense	Special Operations Command	68,551	-	47QFSA22F0056
12	RD	Yes	Department of Defense	Special Operations Command	123,750	-	47QFSA22F0057
12	RD	Yes	Department of Defense	Special Operations Command	39,107	-	47QFSA22F0059
12	RD	Yes	Department of Defense	Special Operations Command	64,487	-	H9240322F0036

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

12	RD	Yes	Department of Defense	Special Operations Command	6,906	-	H92222-17-D-0001
12	RD	Yes	Department of Defense	Special Operations Command	85,632	-	H9240322F0050
12	RD	Yes	Department of Defense	Special Operations Command	24,375,844	330,870	FA8075-16-D-0002 / FA807517F1370
12	RD	Yes	Department of Defense	Special Operations Command	(17,592)	-	W911NF-18-F-0002
12	RD	Yes	Department of Defense	Special Operations Command	2,101	-	H92222-16-D0043 H9240320F0013
12	RD	Yes	Department of Defense	Special Operations Command	344,448	-	H92222-17-D-0001 / H9240220F0007
12	RD	Yes	Department of Defense	Special Operations Command	1,626,691	-	Contract 47QFSA20D0001 / Order 47QFSA20F0021
12	RD	Yes	Department of Defense	Special Operations Command	2,280,313	-	H9240120C0005
12	RD	Yes	Department of Defense	Special Operations Command	35	-	47QFSA20D0001-47QFSA20F0060
12	RD	Yes	Department of Defense	Special Operations Command	313,547	-	Contract #47QFSA20D0001; Order
12	RD	Yes	Department of Defense	Special Operations Command	309,981	75,638	Contract #47QFSA20D0001, Order #47QFSA20F0099, ACT #A22068266
12	RD	Yes	Department of Defense	Special Operations Command	139,044	53	Contract #47QFSA20D0001, Order #47QFSA20F0103, ACTS # A22067898,
12	RD	Yes	Department of Defense	Special Operations Command	145,459	-	H92222-16-D-0043 / H9240321F0013
12	RD	Yes	Department of Defense	Special Operations Command	53,591	-	47QFSA20D0001-47QFSA21F0016
12	RD	Yes	Department of Defense	Special Operations Command	12,256	-	47QFSA20D0001-47QFSA21F0015
12	RD	Yes	Department of Defense	Special Operations Command	1,511,688	-	H92222-16-D- 0043/ H9240321F0053
12	RD	Yes	Department of Defense	Special Operations Command	837,300	-	H92222-17-D0001
12	RD	Yes	Department of Defense	Special Operations Command	1,729,056	-	H92222-16-D- 0043 / H9240321F0066
12	RD	Yes	Department of Defense	Special Operations Command	695,719	2,362	H92222-17-D-0001 / H9240221F0034
12	RD	Yes	Department of Defense	Special Operations Command	1,333	-	H92222-16-D-0043 / H9240321F0057
12	RD	Yes	Department of Defense	Special Operations Command	59,701	35,707	47QFSA20D0001-47QFSA21F0135 Task Order 010
12	RD	Yes	Department of Defense	Technical Information Center	242,832	-	FA8075-16-D-0002/FA807518F1460
12	RD	Yes	Department of Defense	Technical Information Center	2,085,416	409,501	FA8075-16-D-0002/FA807518F1537
					257,599,780	59,529,327	
19	RD	Yes	Department of State	Bureau of International Organization Affairs	2,161,693	-	19AQMM21C0123
					2,161,693	-	
20	RD	Yes	Department of Transportation	Federal Aviation Administration	359,560	-	692M15-18-T-00015
20	RD	Yes	Department of Transportation	Federal Aviation Administration	1,180,940	4,192	692M15-20-C-00026
20	RD	Yes	Department of Transportation	Federal Highway Administration	29,663	-	693JJ322A000001
20	RD	Yes	Department of Transportation	Federal Highway Administration	35,296	-	693JJ322A000001; PO 693JJ322F00170N
20	RD	Yes	Department of Transportation	Federal Highway Administration	136	-	693JJ322A000010
20	RD	Yes	Department of Transportation	Federal Highway Administration	64,832	-	WSDOT Agreement Number: UCB 1249
20	RD	Yes	Department of Transportation	Federal Highway Administration	1,980	-	DTFH6113D00012L
20	RD	Yes	Department of Transportation	Federal Highway Administration	46,254	15,889	DTFH6116D00049L
20	RD	Yes	Department of Transportation	Federal Highway Administration	79,214	75,735	DTFH6116D00038L
20	RD	Yes	Department of Transportation	Federal Highway Administration	52,580	-	DTFH6116D00049L Task Order 693JJ319F000284
20	RD	Yes	Department of Transportation	Federal Highway Administration	12,889	4,671	DTFH6116D00049L Order 693JJ319F000300
20	RD	Yes	Department of Transportation	Federal Highway Administration	307,927	221,367	DTFH6116D00049L ORDER 693JJ319F000383
20	RD	Yes	Department of Transportation	Federal Highway Administration	1,219	1,000	693JJ320F000193 DTFH6116D00049L
20	RD	Yes	Department of Transportation	Federal Highway Administration	24,006	23,987	693JJ319D000006
20	RD	Yes	Department of Transportation	Federal Highway Administration	337,600	148,147	DTFH6116D00049L Order 693JJ320F000361
20	RD	Yes	Department of Transportation	Federal Highway Administration	245,214	77,274	DTFH6116D00049L / 693JJ320F000399
20	RD	Yes	Department of Transportation	Federal Highway Administration	95,411	46,225	DTFH6116D00049L / 693JJ320F000438
20	RD	Yes	Department of Transportation	Federal Highway Administration	71,883	54,182	DTFH6116D00049L / 693JJ321F000012
20	RD	Yes	Department of Transportation	Federal Highway Administration	224,617	159,706	DTFH6116D00049L / 693JJ321F000061
20	RD	Yes	Department of Transportation	Federal Highway Administration	97,272	23,395	693JJ321F000213 693JJ319D000006
20	RD	Yes	Department of Transportation	Federal Highway Administration	176,746	159,339	693JJ321F000438
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	3,066	-	DTNH22-17-D-00033 - DTNH2217F0
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	236,296	136,546	DTNH2217D00033
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	132,976	99,828	DTNH2217D00033 / 693JJ918F000228
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	7,504	-	DTNH2214D00327L / 693JJ918F000211
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	407,927	102,092	693JJ918D000003
20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	1,479	-	DTNH2217D00033 / 693JJ919F000187

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

20	RD	Yes	Department of Transportation	National Highway Traffic Safety Administration	409,902	207,305	693JJ918D000003 / 693JJ920F000160
20	RD	Yes	Department of Transportation	Transportation Security Administration	259,900	-	GS-00F-084CA/70T04022F7672N001
					4,904,289	1,560,880	
43	001	Yes	National Aeronautics and Space Administration	Earth Science Division	130,512	62,614	80NSSC20K1730
43	001	Yes	National Aeronautics and Space Administration	Earth Science Division	91,019	-	80NSSC21K0190
43	001	Yes	National Aeronautics and Space Administration	Science	6,499	-	80NSSC22K0472
43	001	Yes	National Aeronautics and Space Administration	Science	16,662	-	80NSSC22K1097
43	RD	Yes	National Aeronautics and Space Administration	Glenn Research Center	616,750	-	80GRC019C0035
					861,442	62,614	
47	070	Yes	National Science Foundation	Computer and Information Science and Eng	217,165	-	2022042
47	074	Yes	National Science Foundation	Biological Sciences	63,501	-	2201182
47	074	Yes	National Science Foundation	Biological Sciences	(366)	-	DBI-1638695
47	074	Yes	National Science Foundation	Biological Sciences	67,731,915	2,451,731	CSAs 1638696 & 1724433
47	074	Yes	National Science Foundation	Biological Sciences	3,302	-	1744849
47	074	Yes	National Science Foundation	Biological Sciences	7,477	-	1802728
47	074	Yes	National Science Foundation	Biological Sciences	816	-	1925786
47	074	Yes	National Science Foundation	Biological Sciences	12,846	-	2106138
47	078	Yes	National Science Foundation	Polar Programs	55,086	24,120	1936608
47	078	Yes	National Science Foundation	Polar Programs	8,396	-	2045880
47	RD	Yes	National Science Foundation	Office of Polar Programs	43,520,904	25,664,525	49100420C0001
					111,621,042	28,140,376	
66	931	Yes	Environmental Protection Agency	International Financial Assistance Projects - Inter. And Tribal Affairs	618,064	14,505	83617201
66	RD	Yes	Environmental Protection Agency	Ambient Monitoring Technology Information Center	82,899	-	GS00F084CA/EP-G17D-00215
66	RD	Yes	Environmental Protection Agency	Ambient Monitoring Technology Information Center	380,641	25,925	68HE0H18D0009
66	RD	Yes	Environmental Protection Agency	Ambient Monitoring Technology Information Center	282,952	17,673	68HERD21A0001 / 68HERH21F0328
66	RD	Yes	Environmental Protection Agency	Ambient Monitoring Technology Information Center	569,274	-	68HERD21A0001 / Order 68HERH21F0263
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	313,310	2,591	68HERC21D0002/68HERC22F0036
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	38,664	-	68HERC22F0129
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	169,712	-	68HERC22F0417
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	76,190	-	EP-C-16-014 / TASK ORDER 68HERC19F0090
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	212,484	-	EP-C-16-014 - 68HERC19F0117
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	232,054	-	EP-C-16-014 / Task Order 68HERC19F0123
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	1,569	-	EP-C-16-014 / Task Order No. 68HERC19F0208
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	110,445	-	EP-C-16-014 - Task Order No. 68HERC20F0110
66	RD	Yes	Environmental Protection Agency	Homeland Security Research Center	86,600	-	EP-C-16-014 / Task Order No. 68HERC20F0187
66	RD	Yes	Environmental Protection Agency	Office of Air Quality Planning and Standards	58,060	-	68HERD21A0001
66	RD	Yes	Environmental Protection Agency	Office of Air Quality Planning and Standards	20,037	-	68HERH22F0066 68HERD21A0001
66	RD	Yes	Environmental Protection Agency	Office of Air Quality Planning and Standards	10,088	-	68HERH22F0305 68HERD21A0001
66	RD	Yes	Environmental Protection Agency	Office of Air Quality Planning and Standards	74,991	-	68HERD21A0001/68HERH21F0318
66	RD	Yes	Environmental Protection Agency	Office of Pollution Prevention	378,761	82,334	EP-W-16-017 - Option Period 6
66	RD	Yes	Environmental Protection Agency	Office of Pollution Prevention	211,959	11,536	EP-W-16-017 - Option Period 7
66	RD	Yes	Environmental Protection Agency	Office of Pollution Prevention	46,114	-	EP-W-16-017 - Option Period 8
66	RD	Yes	Environmental Protection Agency	Office of Pollution Prevention	260,752	27,112	EP-W-16-017 - Option Period 5
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	31,313	-	68HERC21D0002
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	373,377	58,495	EP-C-16-014
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	745	-	EP-C-16-014 - 68HERC19F0062
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	160,051	-	EP-C-16-014 / Task Order No. 68HERC20F0006
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	321,516	-	EP-C-16-014 / Task Order No. 68HERC20F0065
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	105,135	98	EP-C-16-014 / Task Order No. 68HERC20F0184
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	230,787	-	EP-C-16-014 / Task Order No. 68HERC20F0190
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	255,484	-	EP-C-16-014 / Task Order No. 68HERC20F0204
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	78,909	-	EP-C-16-014 / Task Order No. 68HERC20F0237

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

66	RD	Yes	Environmental Protection Agency	Office of Research and Development	455,143	-	EP-C-16-014 / Task Order No. 68HERC20F0220 / PO No. C2000005121
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	39,627	-	EP-C-16-014 / Task Order No. 68HERC20F0231 / PO No. C2000005141
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	479,932	-	EP-C-16-014 / Task Order No. 68HERC20F0241
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	73,558	-	EP-C-16-014 / Task Order No. 68HERC20F0403
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	35	-	EP-C-16-014 / Task Order No. 68HERC20F0449
66	RD	Yes	Environmental Protection Agency	Office of Research and Development	128,815	-	68HERC21D0002 / Task Order No. 68HERC21F0149
66	RD	Yes	Environmental Protection Agency	Office of Science	877,535	124,671	68HE0H18D0009/68HERH19F0400
66	RD	Yes	Environmental Protection Agency	Risk Management Research Lab	1,651,950	82,269	EP-C-16-014 / TASK ORDER 0002
					9,499,532	447,209	
81	049	Yes	Department of Energy	Office of Science Financial Assistance Program	227,495	-	DE-SC0022026
81	086	Yes	Department of Energy	Conservation Research and Development	92,081	10,522	DE-EE0009299
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	228,579	143,584	DE-FE0031686
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	595,971	123,633	DE-FE0031782
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	84,384	-	DE-FE0031795
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	634,500	252,765	DE-FE0031792
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	3,912,178	1,402,649	DE-FE0031836
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	949,874	68,061	DE-FE0031850
81	089	Yes	Department of Energy	National Energy Technology Lab - Fossil Energy Research and Development	258,475	118,423	DE-FE0032062
					6,983,537	2,119,637	
93	103	Yes	Department of Health and Human Services	Food & Drug Administration - Research Misconduct	131,711	-	5U01FD007359-02
93	273	Yes	Department of Health and Human Services	Alcohol Research Programs	125,256	17,923	1R01AA024709-01A1
93	393	Yes	Department of Health and Human Services	National Cancer Institute - Cancer Cause & Prevention Research	137,120	-	1R21CA263809-01
93	077	Yes	Department of Health and Human Services	Family Smoking Prevention and Tobacco Control Act Regulatory Research	592,104	-	1R01ES033016-01
93	077	Yes	Department of Health and Human Services	National Institutes of Health	3,316	-	1R21CA244305-01
93	RD	Yes	Department of Health and Human Services	Agency for Toxic Substances and Disease	73,207	-	75D30120C08057
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	690,541	119,062	HHSO1002015000041
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	31,709	-	HHSO1002017000111
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	23,436	-	HHSO1002017000111 / HHSO10033001T / BIO-AMT-1004
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	101,672	-	HHSO1002017000111/HHSO10033004T / RTOR-BIO-AMT-1008
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	75,776	20,318	HHSO1002017000111/HHSO10033005T / RTOR-BIO-AMT-1005
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	51,732	20,334	HHSO1002017000111/HHSO10033006T / RTOR-BIO-AMT-1006
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	160,720	26,209	HHSO1002015000041 / HHSO10033003T
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	60,600	234	HHSO1002017000111 / HHSO10033007T / RTOR-BIO-AMT-1016
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	1,371,642	632,455	HHSO1002017000111 / 75A50119F33009 / RTOR-BIO-AMT-1017
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	1,510,483	236,140	HHSO1002017000111 / 75A50119F33010 / RTOR-BIO-AMT-1018
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	153,150	-	HHSO1002017000111 / 75A50119F33011 / RTOR-BIO-AMT-1019
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	1,234,510	2,500	HHSO1002017000111 / 75A50120F33012 / RTOR-BIO-AMT-1021
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	2,298,093	311,392	HHSO1002015000041 / 75A50120F33004 / RTOR-CHEM-1005
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	124,681	7,331	HHSO1002017000111 / 75A50121F33014 / RTOR-BIO-AMT-1022
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	82,168	-	HHSO1002017000111 75A50121F33013
93	RD	Yes	Department of Health and Human Services	Biomed Advanced Research Development Authority	1,179,880	60,000	75A50121F33015
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	406,733	-	200-2016-89243
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	516,117	-	HHSD2002013M53942B
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	6,376	10,792	GS00Q14OADU402-75D301-18-F-00788
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	464,021	-	GS-00F-084CA/HHSD2002013M53942B/ORDER, 75D30118F03460/SIN 874-1/00HCUGDH-2018-25857
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	488,374	-	Contract GS00Q14OADU402 Order No. 75D30119F06822
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	4,591,187	-	GS00F084CA/75D30119F06700
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	1,070,550	79,704	Contract GS00Q14OADU102 / Order 75D30120F08954
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	2,683,457	263,026	75D30120F09238
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control	529,343	-	75D30121C11398
93	RD	Yes	Department of Health and Human Services	Centers for Disease Control and Prevention	2,870,024	-	75D30121F12217 GS00Q14OADU402
93	RD	Yes	Department of Health and Human Services	Centers for Medicare & Medicaid Services	4,185,289	67,087	75FCMC18D0018
93	RD	Yes	Department of Health and Human Services	Food & Drug Administration	748,999	150,937	75F40119D10010/75F40119F19001

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

93	RD	Yes	Department of Health and Human Services	Food & Drug Administration	394,501	166,065	75F40119D10010/75F40119F19002
93	RD	Yes	Department of Health and Human Services	Food & Drug Administration	95,409	-	75F40120P00544
93	RD	Yes	Department of Health and Human Services	Food & Drug Administration	219,610	-	75F40119D10010/75F40120F19003
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	750,341	262,904	HHSN2722012000031 / HHSN27200026
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	276,257	-	HHSN272201700012I
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	86,721	-	Contract Number: HHSN272201700012I; Task Order Number: HHSN27200006; Task: B03 / 75N93018F00006
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	119,174	-	HHSN2722018000131 (75N93018D00013) / HHSN27200001
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	1,171,340	469,720	HHSN2722018000131 (75N93018D00013)/ 75N93019F00131 / TOV2
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	11,862	-	HHSN2722018000131 (75N93018D00013) / 75N93019F00366 / TOV3
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	13,268	-	HHSN2722018000131
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	7,438	-	75N93022F00002 HHSN2722018000131
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	5,906	-	75N93022F00003
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	24,237	-	75N93022F00004 HHSN2722018000131
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	20,105	-	75N93022F00005 HHSN2722018000131
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	148,312	-	HHSN2722012000031
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	62,841	51,567	HHSN272201200003I ORDER NO. HH
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	39,362	32,300	CONTRACT NO. HHSN272201200003I
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	191	-	Contract No. HHSN272201200003I; Order No. HHSN27200014
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	829,016	485,373	Contract No. HHSN272201200003I; Order No. HHSN27200015
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	146,705	-	HHSN272201200003I/HHSN27200019
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	18,970	-	HHSN2722018000131 (75N93018D00013) / 75N93021F00001 / TO10
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	1,003,732	47,554	FA807518D0016-FA807521F0044
93	RD	Yes	Department of Health and Human Services	National Institute of Allergy and Infectious Disease	51,373	-	HHSN2722018000131 / 75N93021F00002 / TO 11
93	RD	Yes	Department of Health and Human Services	National Institute of Environmental Health	2,947,147	-	HHSN273201400027C
93	RD	Yes	Department of Health and Human Services	National Institute of Environmental Health	17,781,016	8,358,852	HHSN273201400015C
93	RD	Yes	Department of Health and Human Services	National Institute of Environmental Health	3,197,136	534,052	HHSN273201700005C
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	1,750	-	SP0700-00-D-3180-0794
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	136,921	92,160	HHSN2722012000031 ; Order No. TO 20 HHSN27200020
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	32,235	5,510	HHSP233201500095I-HHSP2333701T
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	113,523	37,404	HHSN2722012000031 / HHSN27200021
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	465,431	-	HHSN272201200003I/HHSN27200024
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	1,988	-	HHSN272201200003I- HHSN2720002
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	424,848	-	HHSN2722018000131 (75N93018D00013)/ 75N93020F00001 / TO 4
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	180,694	82,597	HHSN271201700015I
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	329,912	236,502	HHSN271201700015I / 75N95020F00001
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	1,207,185	-	Contract Number: HHSN272201700012I; Task Order Number: 75N93020F00001; Task: B08
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	2,702,376	837,768	HHSN2722018000131 (75N93018D00013) / 75N93020F00002 / TO 5
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	702,000	115,711	HHSN2722018000131 (75N93018D00013) / 75N93020F00003 / TO6
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	127,995	-	HHSN2722018000131 (75N93018D00013) / 75N93020F00005 / TO 8
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	9,240	-	HHSN2722018000131 (75N93018D00013) / 75N93020F00004 / TO7
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	276	-	HHSN271201700015I / 75N95020F00003
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	1,569,726	1,018,261	HHSN271201700015I / 75N95020F00002
93	RD	Yes	Department of Health and Human Services	National Institutes of Health	317,970	-	HHSN2722018000131 (75N93018D00013) / 75N93020F00006
					66,520,017	14,859,744	
97	RD	Yes	Department of Homeland Security	Countering Weapons of Mass Destruction Office	54,481	-	70RWMD22C00000014
97	RD	Yes	Department of Homeland Security	Domestic Nuclear Detection Office	189,117	91,764	FA8075-14-D-0003 DO 0010
97	RD	Yes	Department of Homeland Security	Domestic Nuclear Detection Office	12,030,355	2,245,066	FA8075-14-D-0003/FA8075-18-F1414
97	RD	Yes	Department of Homeland Security	Federal Emergency Management Agency	3,753,776	-	SPE8EJ-20-D-0501 - SPE8EJ-20-F
97	RD	Yes	Department of Homeland Security	Federal Emergency Management Agency	(72)	-	SPE8EJ-20-D-0501 / SPE8EJ-20-F-039E
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	2,209,786	445,205	FA807518D0016
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	3,579,700	545,406	70RSAT19CB0000014
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	340,395	-	70RSAT18D00000003 / 70RSAT19FR0000043
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	1,642,195	-	70RSAT18D00000003 / 70RSAT19FR0000018
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	582,807	84,252	70RSAT18D00000003 / 70RSAT19FR0000053

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	375,774	-	70RSAT18D00000003 / 70RSAT19FR0000061
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	875,212	482,461	70RSAT18D00000003 / 70RSAT19FR0000136
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	287,212	47,603	70RSAT18D00000003 / 70RSAT19FR0000159
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	564,172	-	70RSAT18D00000003 / 70RSAT20FR0000151 TO 17
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	8,444,785	989,451	FA807618D0016 / Order FA807521F0073
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	927,120	299,125	70RSAT18D00000003 / 70RSAT21FR0000039
97	RD	Yes	Department of Homeland Security	Science and Technology Directorate	377,774	-	70RSAT18D00000003 / 70RSAT21FR0000115 TO 22
97	RD	Yes	Department of Homeland Security	Secret Service	512,303	-	70US0921A70090038
97	RD	Yes	Department of Homeland Security	Transportation Security Administration	1,756	1,420	GS-00F-084CA, CON. HSTS04-15-A
97	RD	Yes	Department of Homeland Security	Transportation Security Administration	-	-	GS-00F-084CA, CON. HSTS04-15-A-CT6005 - ORDER 70T04020F1NAP6616 BPA 22 SIN C871-4
97	RD	Yes	Department of Homeland Security	Transportation Security Administration	159,299	115,038	HSTS04-15-A-CT6005 - 70T04020F
97	RD	Yes	Department of Homeland Security	Transportation Security Administration	51,895	17,231	HSTS04-15-A-CT6005 - DO 70T040
97	RD	Yes	Department of Homeland Security	Transportation Security Administration	3,605,461	1,342,050	70T04021A7672N002
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	277,613	-	70RSAT21FR0000135
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	541,730	-	70RSAT18D00000003
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	216,471	13,374	70RSAT22FR0000063;OPP212207
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	485,834	-	OPP212203
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	10,959	-	70RSAT22FR0000123
97	RD	Yes	Department of Homeland Security	Transportation Security Laboratory	3,120,580	210,098	GS00Q14OADU102/70RSAT18FR0000168
97	RD	Yes	Department of Homeland Security	US Secret Service	1,963,797	10,970	70QS0320C00000005
					47,182,287	6,940,514	
Total Direct Funding					\$ 507,474,705	\$ 113,717,001	

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

Agency Code	CFDA	R&D	Federal Agency	Prime/Upper Tier Contractor	Total Expenditures	Subcontracted Dollars	Contract Ref.
2. Indirect Funding (Battelle is Sub recipient/subcontractor)							
12	910	Yes	Department of Defense	UNIVERSITY OF CALIFORNIA - DAVIS	\$ 929,061	\$ -	N66001-20-2-4046
12	RD	Yes	Department of Defense	300 Below Inc	2,644	-	PO 07152019-SB / OPP211575
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	12,423	-	N001742290011
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	624,987	99,808	2010-365
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	13,056,599	7,622,938	2018-865-001 / MCDC-18-06-16-005
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	3,968,797	2,014,575	MCDC2001-010 / 2018-865-04
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	14,118	-	2019-370/ Project Agreement 03
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	1,379	-	2019-370 - Project Agreement N
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	503,570	29,590	2018-865-002 / MCDC1911-003
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	68,575	-	2019-370 / Project Agreement No. 02
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	4,553,775	948,671	2018-865-03/MCDC2002-002
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	167,989	-	W9124P-19-9-0001
12	RD	Yes	Department of Defense	ADVANCED TECHNOLOGY INTERNATIONAL	650,235	-	AMTC-20-02-076
12	RD	Yes	Department of Defense	AEROCLOVE LLC	87,578	-	JBADS DOR 20180404, Amend 0003
12	RD	Yes	Department of Defense	Alion Science and Technology Corporation	865,168	108,770	SUB1132280-003
12	RD	Yes	Department of Defense	Alion Science and Technology Corporation	1,035,453	657	HDTRA1-14-D-0002
12	RD	Yes	Department of Defense	Applied Research Associates Inc	1,118,685	-	HDTRA1-19-D-0007
12	RD	Yes	Department of Defense	Applied Research Associates Inc	186,503	-	S-D00189-02-TO-02-BATTELLE / HDTRA1-19-D-0007
12	RD	Yes	Department of Defense	Bechtel National Inc	366,128	-	W52P1J-09-C-0013
12	RD	Yes	Department of Defense	Bechtel National Inc	9,340	-	BNI_BM_24915-300-FC4-HXYT-00002 / SubCLIN 008
12	RD	Yes	Department of Defense	Bechtel National Inc	47,902,426	162	24915-300-FC4-HXYT-00002 CO #94
12	RD	Yes	Department of Defense	Bechtel National Inc	4,832,728	-	24915-300-FC4-HXYT-C0002 CO154
12	RD	Yes	Department of Defense	Bechtel National Inc	49,786,328	114,452	W52P1J-09-C-0012
12	RD	Yes	Department of Defense	Bechtel National Inc	719,536	-	SCN-105
12	RD	Yes	Department of Defense	Booz-Allen-HAMILTON	292,768	-	GS00Q14OADU108/W911QY20F0412
12	RD	Yes	Department of Defense	Booz-Allen-HAMILTON	199,797	-	S900401BAH (A1237 - P22198) TO 005
12	RD	Yes	Department of Defense	Booz-Allen-Hamilton Inc	135,332	-	S901871BAH - 54001-1041
12	RD	Yes	Department of Defense	Booz-Allen-Hamilton Inc	(721)	-	S900401BAH TO 0004
12	RD	Yes	Department of Defense	Business Sensitive	2,906,632	-	FA8750-21-C-1501
12	RD	Yes	Department of Defense	Business Sensitive	594,899	-	FA8750-21-F-1000
12	RD	Yes	Department of Defense	Business Sensitive	3,144,365	-	5300034747
12	RD	Yes	Department of Defense	Business Sensitive	620,739	-	Proprietary
12	RD	Yes	Department of Defense	Business Sensitive	942,811	-	Subcontract A000494527
12	RD	Yes	Department of Defense	Business Sensitive	4,946,537	10,746	PO CW-2020-100
12	RD	Yes	Department of Defense	Business Sensitive	90,756	-	1096.04-SP
12	RD	Yes	Department of Defense	Business Sensitive	187,567	-	ATL-2020-01-OH
12	RD	Yes	Department of Defense	Business Sensitive	373,961	-	ATP Dated 8/14/2020
12	RD	Yes	Department of Defense	CH2M Hill	360,970	-	Purchase Order No. 148019700
12	RD	Yes	Department of Defense	CH2M Hill	906,195	-	
12	RD	Yes	Department of Defense	CH2M Hill Inc	92,876	-	HDTRA1-18-D-0007
12	RD	Yes	Department of Defense	CH2M Hill Inc	(676)	-	HDTRA1-08-D-0008
12	RD	Yes	Department of Defense	Charles River Analytics, Inc.	34,267	-	SC1932401
12	RD	Yes	Department of Defense	CMC Pharmaceuticals Inc	48,915	-	Services Agreement Number OPP2
12	RD	Yes	Department of Defense	Collaborations Pharmaceuticals, Inc.	262,998	-	OPP208969R2
12	RD	Yes	Department of Defense	Design Interactive, Inc.	55,263	-	MTEC-18-09-APPEAR-015
12	RD	Yes	Department of Defense	Dynport Vaccine LLC	8,708	-	DAMD17-98-C-8024
12	RD	Yes	Department of Defense	Dynport Vaccine LLC	2,231	-	Subcontract Number S100821840 / Task Order 40
12	RD	Yes	Department of Defense	Dynport Vaccine LLC	155	-	Subcontract Number S100821841 / Task Order 41
12	RD	Yes	Department of Defense	Emory University	62,818	-	Services Agreement OPP220644
12	RD	Yes	Department of Defense	ES3 Prime Logistics Group	697	-	FA8222-21-C-5012

148017723

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

12	RD	Yes	Department of Defense	FLIR DETECTION INC	68,617	-	W15QKN-18-9-1004
12	RD	Yes	Department of Defense	GD-OTS Machining Operations	6,762	-	17-SC-0077
12	RD	Yes	Department of Defense	Halvik Corporation	610,916	-	47QRAD20D1046
12	RD	Yes	Department of Defense	Harris Corporation	1,098,486	-	A000486740 - A000464676
12	RD	Yes	Department of Defense	Harris Corporation	123	-	A000532164
12	RD	Yes	Department of Defense	Harris Corporation	345,658	-	PO A000563678
12	RD	Yes	Department of Defense	Humanetics Corporation	412,697	-	Agreement Number OPP215595R
12	RD	Yes	Department of Defense	Huntington Ingalls Industries	59,775	-	W911SR-16-D-0012/W911SR21F0006
12	RD	Yes	Department of Defense	InnovaSystems International	41,095	-	N0017819D7833 / N0018922F3014
12	RD	Yes	Department of Defense	Karagozian & Case Inc.	66	-	Purchase Order No. B1190382
12	RD	Yes	Department of Defense	KPMG LLP	558,855	151,579	Battelle.FIAR.USMC.TOF0015
12	RD	Yes	Department of Defense	L3 COMMUNICATIONS	20,297	-	N00019-14-D-0011
12	RD	Yes	Department of Defense	L3Harris Technologies Inc	1,570	-	Letter Contract # 4500253681
12	RD	Yes	Department of Defense	LEIDOS INC	49,183	-	W52P1J-18-C-0047
12	RD	Yes	Department of Defense	LEIDOS INC	115,984	-	PO10221292
12	RD	Yes	Department of Defense	LEIDOS INC	1,798,093	-	P010254004
12	RD	Yes	Department of Defense	Logistics Management Institute	254,101	-	2018-876/02
12	RD	Yes	Department of Defense	MANTECH INTERNATIONAL CORP	1,070,385	-	N4175621C4351
12	RD	Yes	Department of Defense	Microsoft Corporation	1,363	-	NSXTL PO# N00164-20-9-G009b
12	RD	Yes	Department of Defense	MSI Defense Solutions	10,234	-	Purchase Order No. 92886
12	RD	Yes	Department of Defense	Nanotherapeutics Inc	80	-	P1013591
12	RD	Yes	Department of Defense	Nimbus Services Inc	54	-	Nimbus-F-1894-Battelle
12	RD	Yes	Department of Defense	Ology Bioservices, Inc	113,567	-	OPP217574
12	RD	Yes	Department of Defense	Ology Bioservices, Inc	437,038	-	PO No. P1024274
12	RD	Yes	Department of Defense	Ology Bioservices, Inc	297,358	-	PO #P1023882, OPP214777R2; PO #P1025946, OPP215490R; PO #P1027812, OPP217498
12	RD	Yes	Department of Defense	Ology Bioservices, Inc	227,257	-	Purchase Order No. P1028818
12	RD	Yes	Department of Defense	Par Government Systems	128,054	-	FA8750-20-C-1021
12	RD	Yes	Department of Defense	Qualis Corporation	193,282	-	FA7046-18-D-0003-0007
12	RD	Yes	Department of Defense	R Dorsey & Company Inc	251,556	-	W15QKN-20-R-0C8M
12	RD	Yes	Department of Defense	Resilience	12,879	-	W911QY-20-9-0003
12	RD	Yes	Department of Defense	Resilience	1,975,472	-	P1033636
12	RD	Yes	Department of Defense	Resilience	25,341	-	P1035822
12	RD	Yes	Department of Defense	Resilience	10,719	-	P1035826
12	RD	Yes	Department of Defense	Reynolds Systems Inc	374	-	PO-001353
12	RD	Yes	Department of Defense	Rochester Institute of Technology	69,737	-	32588-01
12	RD	Yes	Department of Defense	Science Applications Internation Corporation	81,998	443	P010243457
12	RD	Yes	Department of Defense	Signature Science LLC	122,950	-	S1044
12	RD	Yes	Department of Defense	Spark Biomedical Inc	75,426	-	STTR Phase I - A21C-T024-0261
12	RD	Yes	Department of Defense	Spectrohm Inc	10,379	-	FA864922P1165
12	RD	Yes	Department of Defense	Strategic Environmental Research and Dev Program	8,753	-	W912HQ22C0037 - OPP217197
12	RD	Yes	Department of Defense	Systems & Technology Research LLC	301	-	Subcontract #: 2018-0049 / Prime Contract # W31P4Q-18-C0067
12	RD	Yes	Department of Defense	Systems & Technology Research LLC	225,650	-	HR001118C0063
12	RD	Yes	Department of Defense	Systems & Technology Research LLC	20,588	-	2018-0058
12	RD	Yes	Department of Defense	Systems & Technology Research LLC	148	-	FA8750-16-C0137
12	RD	Yes	Department of Defense	Systems & Technology Research LLC	649,556	-	10303 2021-0006
12	RD	Yes	Department of Defense	TDA RESEARCH INC	77,076	-	Services Agreement OPP215406
12	RD	Yes	Department of Defense	TDA RESEARCH INC	16,341	-	OPP209126 - 1401.003.BF.BMI.18
12	RD	Yes	Department of Defense	Teledyne Brown Engineering	95,885	-	OPP214361
12	RD	Yes	Department of Defense	Teledyne Inc	1,086	-	PEM1025
12	RD	Yes	Department of Defense	UES Inc.	809	-	FA8650-16-D-5851 TO 4
12	RD	Yes	Department of Defense	UTC Aerospace Systems	655,850	-	Subcontract 10853241
					160,044,709	11,102,391	
15	RD	Yes	Department of Interior	BB&E Inc	585	-	WORK ORDER NO. 02077001-001
					585	-	

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

16	560	Yes	Department of Justice	WEST VIRGINIA UNIVERSITY	68,600	-	20-763-BMI
					68,600	-	
17	RD	Yes	Department of Labor	Decision Information Resources	822,929	-	1630DC-18-F-00034
					822,929	-	
20	RD	Yes	Department of Transportation	Dunlap and Associates, Inc.	270	-	DTNH2216D00023
20	RD	Yes	Department of Transportation	TERRACON CONSULTANTS INC	5,942	-	Purchase Order No. P00038722
					6,212	-	
43	003	Yes	National Aeronautics and Space Administration	University of Alaska Fairbanks	3,683	-	P0557973
43	RD	Yes	National Aeronautics and Space Administration	California Institute of Technology	126	-	1684320 NEON AA 2021-091
43	RD	Yes	National Aeronautics and Space Administration	Case Western Reserve University	860	-	65L-S435932 Rev 2
43	RD	Yes	National Aeronautics and Space Administration	University of Maryland	2,354	-	NEON AA 2022-13.49;OPP221770
					7,023	-	
45	RD	Yes	National Foundation on the Arts and the Humanities	OCLC Inc	66,714	-	11177
					66,714	-	
47	050	Yes	National Science Foundation	University of Alaska Fairbanks	4,802	-	2131914
47	070	Yes	National Science Foundation	The Ohio State University	5,504	-	2118240
47	074	Yes	National Science Foundation	Cleveland State University	57	-	OPP222196
47	074	Yes	National Science Foundation	Colorado State University	10,202	-	
47	074	Yes	National Science Foundation	Colorado State University	583	-	PO 735018
47	074	Yes	National Science Foundation	Colorado State University	132,242	-	PO 749084
47	074	Yes	National Science Foundation	Dartmouth College	7,312	-	award #1844531;OPP221103
47	074	Yes	National Science Foundation	Denver Botanic Gardens	5,197	-	OPP220218
47	074	Yes	National Science Foundation	DePaul University	7,311	-	PO# DEP0000203081
47	074	Yes	National Science Foundation	Florida State University	29,153	11,268	FS22038801;OPP221792
47	074	Yes	National Science Foundation	NORTHERN ARIZONA UNIVERSITY	28,803	-	2000122465 / OPP214159
47	074	Yes	National Science Foundation	President and Fellows of Middlebury Coll	4,168	-	OPP216727
47	074	Yes	National Science Foundation	University Corporation for Atmospheric R	54,858	-	2039932
47	074	Yes	National Science Foundation	University of California Irvine	3,570	-	Subaward # 2020-1423
47	074	Yes	National Science Foundation	University of Nebraska	20,580	-	2106075
47	074	Yes	National Science Foundation	University of Utah	725	-	OPP211746 - PO# U000235262
47	074	Yes	National Science Foundation	University of Wisconsin-Madison	2,820	-	22-8739;MSN0101516
47	074	Yes	National Science Foundation	University of Wisconsin-Madison	6,610	-	Subaward # 840K906
47	074	Yes	National Science Foundation	VIRGINIA POLYTECHNIC INSTITUTE & STATE U	26,371	-	OPP211855
47	074	Yes	National Science Foundation	WEST VIRGINIA UNIVERSITY	2,200	-	Subaward No. 21-310-BMI
47	074	Yes	National Science Foundation	Woodwell Climate Research Center Inc	52,243	-	WOODWELL-NG0471-02
47	RD	Yes	National Science Foundation	Colorado State University	1,848	-	PO# 704187
47	RD	Yes	National Science Foundation	DUKE UNIVERSITY	955	-	DEB-1754443
47	RD	Yes	National Science Foundation	University of Alaska Fairbanks	186,490	172,000	P0548061
47	RD	Yes	National Science Foundation	University of Utah	1,802	-	PO U000261105
47	RD	Yes	National Science Foundation	University of Wisconsin-Madison	13,794	-	20-8374 / PO # 953K503 or PO # 023L413
					610,200	183,268	
66	509	Yes	Environmental Protection Agency	The Ohio State University	119,815	-	84024101
66	RD	Yes	Environmental Protection Agency	Pegasus Technical Services Inc	(2,397)	-	BMI-16-001, Mod 5
66	RD	Yes	Environmental Protection Agency	Research Triangle Institute Inc	2,599,745	-	EP-C-17-045
66	RD	Yes	Environmental Protection Agency	Research Triangle Institute Inc	1,403,633	49,006	Prime Contract No. EP-C-17-045-Subcontract No. 6-312-0216039-65673L-Task Order 006 / Vendor 020445
					4,120,796	49,006	

759372

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

81	087	Yes	Department of Energy	University of Utah	233,016	91,282	DE-EE007080
81	089	Yes	Department of Energy	CONSOL ENERGY INC	998,377	238,516	DE-FE0031998
81	089	Yes	Department of Energy	SOUTHERN STATES ENERGY BOARD	30,269	-	SSEB-SEOFFS-921-BATTELLE-2018-001
81	089	Yes	Department of Energy	SOUTHERN STATES ENERGY BOARD	22,051	-	DE-FE0031888
81	089	Yes	Department of Energy	TEXAS A & M UNIVERSITY	62,870	-	SUBRECIPIENT AGREEMENT NO. M1803977 / TAMUS Account No. 28-51101000002
81	089	Yes	Department of Energy	University of Illinois	7,537	-	SUBAWARD Number 101914-18218
81	089	Yes	Department of Energy	University of Wyoming, Carbon Management	18,191	-	DE-FE0032048
81	RD	Yes	Department of Energy	LEIDOS INC	12,767,302	-	89243318CFE000003
81	RD	Yes	Department of Energy	Mele Associates, Inc.	592,073	-	GS-00F-243CA
81	RD	Yes	Department of Energy	Stoller Corp	5,160	-	Purchase Order No. LMS3836
81	RD	Yes	Department of Energy	University of Wyoming, Carbon Management	7,125	-	DE-FE0031779
					<u>14,743,971</u>	<u>329,798</u>	
93	318	Yes	Department of Health and Human Services	Management Sciences for Health Inc	16,892	-	NU2HGH000073-02
93	837	Yes	Department of Health and Human Services	UNIVERSITY OF MICHIGAN	101,516	-	1R01HL137731-01
93	077	Yes	Department of Health and Human Services	Georgia State University, School of Publ	105,840	-	5R01CA235719-03
93	077	Yes	Department of Health and Human Services	University of Oklahoma Health Sciences C	6,628	-	5R01DA046359-03
93	RD	Yes	Department of Health and Human Services	Avanti Corporation	35,182	-	75N96020D00010
93	RD	Yes	Department of Health and Human Services	Basilea Pharmaceutica International Ltd	557,727	-	Work Order No. 1 - Service Agreement #103085
93	RD	Yes	Department of Health and Human Services	BAVARIAN NORDIC GMBH	391,192	-	Agreement Number OPP214673R2
93	RD	Yes	Department of Health and Human Services	Biofactura, Inc	135	-	OPP212346R2
93	RD	Yes	Department of Health and Human Services	Emergent Biosolutions Inc	3,229	-	Subcontract No. 19591 / Purchase Order 4500041046
93	RD	Yes	Department of Health and Human Services	Emergent Biosolutions Inc	1,340	-	Subcontract No. 19591 - Purcha
93	RD	Yes	Department of Health and Human Services	Emergent Biosolutions Inc	6,767	-	HHSO100201600030C
93	RD	Yes	Department of Health and Human Services	Emergent Biosolutions Inc	38,409	-	Subcontract No. 19591 / Purchase Order 4500060344
93	RD	Yes	Department of Health and Human Services	Enterprise Science and Computing	1,048,334	-	GS-35F-0539X/75FCMC20F0087
93	RD	Yes	Department of Health and Human Services	Hawaii Biotech Inc	424,656	51,639	OPP213468
93	RD	Yes	Department of Health and Human Services	Legacy Devers Eye Institute	62,799	-	Agreement Number OPP214548R2
93	RD	Yes	Department of Health and Human Services	Mapp Biopharmaceutical	545,137	-	HHSO100201900018C
93	RD	Yes	Department of Health and Human Services	Moderna Therapeutics Inc	421	-	Task Order OPP212533 / Study No. B05519
93	RD	Yes	Department of Health and Human Services	Moderna Therapeutics Inc	967	-	Task Order OPP212729 / Study No. B05432
93	RD	Yes	Department of Health and Human Services	Moderna Therapeutics Inc	184	-	Task Order OPP214423 / Study No. T05812
93	RD	Yes	Department of Health and Human Services	Moderna Therapeutics Inc	124,446	-	Task Order OPP215264R / Study No. B05916
93	RD	Yes	Department of Health and Human Services	Modernatx Inc	2,075,753	-	75A50120C00034
93	RD	Yes	Department of Health and Human Services	Modernatx Inc	22,168	-	Task Order OPP219004R
93	RD	Yes	Department of Health and Human Services	Modernatx Inc	246,665	-	Task Order OPP217783 - Study No. VA-6081
93	RD	Yes	Department of Health and Human Services	Paratek Pharmaceuticals	393,541	-	75A50120C00001
93	RD	Yes	Department of Health and Human Services	Paratek Pharmaceuticals	637,914	9,069	Purchase Order No. 3724 - BARDA PRIME CONTRACT NO. 75A50120C00001 - TASK ORDER 001
93	RD	Yes	Department of Health and Human Services	Plowshare Group, Inc.	599,857	-	200-2020-F-09371
93	RD	Yes	Department of Health and Human Services	Rho Inc.	283	-	OPP206346R1
93	RD	Yes	Department of Health and Human Services	Sabin Vaccine Institute	896,571	-	75A50119C00055
93	RD	Yes	Department of Health and Human Services	Sabin Vaccine Institute	240,700	-	Task Order 2 - Clinical Sample Testing: 020434-02
93	RD	Yes	Department of Health and Human Services	Sabin Vaccine Institute	561,554	-	Task Order 3 - NHP Study: 020434-03
93	RD	Yes	Department of Health and Human Services	Tangen Biosciences	140,903	-	Agreement Number OPP208818R1
93	RD	Yes	Department of Health and Human Services	The MITRE Corporation	884,317	-	75FCMC18D0047
					<u>10,172,027</u>	<u>60,708</u>	

BATTELLE MEMORIAL INSTITUTE

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED SEPTEMBER 30, 2022

97	RD	Yes	Department of Homeland Security	Amentum Services, Inc.	427,588	-	FA807514D0024
97	RD	Yes	Department of Homeland Security	Amentum Services, Inc.	67,290	-	FA8075-18-D-0014
97	RD	Yes	Department of Homeland Security	Amentum Services, Inc.	33,699	-	FA807520F0084
97	RD	Yes	Department of Homeland Security	NORTHROP GRUMMAN CORP	223,731	-	Subcontract No. 2300000575
97	RD	Yes	Department of Homeland Security	Steampunk Holdings, Inc.	1,057,014	-	47QTCA20D005E
					<u>1,809,322</u>	<u>-</u>	
Total Indirect Funding					192,473,088	11,725,171	
Total Expenditures of Federal Awards					<u>\$ 699,947,793</u>	<u>\$ 125,442,172</u>	

(Concluded)

BATTELLE MEMORIAL INSTITUTE

NOTES TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED SEPTEMBER 30, 2022

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation—The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (US GAAP). The accompanying consolidated financial statements include all the Company’s wholly owned and financially or otherwise controlled subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation and figures are presented in thousands but for the Schedule of Expenditures and Federal Awards for the year ended September 30, 2022 or unless otherwise stated.

The accompanying schedule of expenditures of federal awards (the “Schedule”) summarizes the expenditures of Battelle Memorial Institute (BMI) and subsidiaries (the “Company”) under programs funded by the federal government for the year ended September 30, 2022. The Schedule has been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America and includes all federal awards and contracts entered into directly between the Company and agencies and departments of the federal government, as well as funds passed through to the Company by other recipients. In accordance with the Uniform Guidance 2 CFR 200 (§200.38 Federal award) the Schedule does not include amounts received to operate government-owned, contractor-operated facilities. Negative amounts reported on the Schedule are adjustments or credits made in the normal course of business to amounts reported as expenditures in prior fiscal years.

Research and Development Cluster (“R&D cluster”)—OMB Uniform Guidance defines research and development as follows: research is a systematic study directed toward fuller scientific knowledge or understanding of the subject studied; development is the systematic use of knowledge and understanding gained from research directed toward the production of useful materials, devices, systems, or methods, including design and development of prototypes and processes. The Company’s work is closely aligned with the R&D cluster of programs in accordance with 2 CFR 200.17 and 2 CFR 200.87. Accordingly, the schedule of expenditures of federal awards reports all reportable programs in the R&D cluster.

Subrecipient—Certain funds are passed through to subgrantee organizations by the Company. Expenditures incurred by the subgrantees and reimbursed by the Company are presented in the Schedule.

The Company is also the subrecipient of funds, which have been reported as expenditures and listed as pass-through funds.

2. NONCASH AWARDS

During the year ended September 30, 2022, the Company did not receive nonmonetary assistance.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES FOR PROGRAM EXPENDITURES

Expenditures consist of direct and indirect costs. Direct costs are those that can be identified specifically with a sponsored project. Indirect costs are the costs of services and resources that benefit both sponsored and non-sponsored projects but are necessary for the operation of the Company.

Battelle Science and Technology (S&T) and Integration segment projects use indirect costs rates to charge indirect costs to individual sponsored projects. The rates are the result of a number of complex cost allocation procedures that the Company uses to allocate its indirect costs to both sponsored and non-sponsored activities. The indirect costs allocated to sponsored projects are divided by the direct costs of sponsored projects to arrive at a rate. These indirect rates are reviewed and approved by the Defense Contract Audit Agency.

Indirect costs included in the expenditures reported by the Battelle Ecology segment are based upon provisional indirect cost rates prescribed by the National Science Foundation and applied to the appropriate allocation base.

The Battelle Education subsidiary has elected to charge the de minimis indirect cost rate of 10% as permitted under the Uniform Guidance.

4. LOANS/LOAN GUARANTEES

Battelle does not have loan balances outstanding at the end of fiscal year 2022 reportable in accordance with §200.502 — “Basis for determining Federal awards expended”.

5. CLASSIFIED INFORMATION

Due to the nature of research and development that the Company performs on behalf of the federal government, various contracts and project information is considered classified, which includes “Top Secret,” “Secret,” or “Confidential.” As a result, the Schedule reflects summarized data by agency in order to properly safeguard various information as required by the federal government.

6. RELATIONSHIP TO CONSOLIDATED FINANCIAL STATEMENTS

Awards in the amount of \$699,947,793 are reported as a portion of total project revenue in the Company’s consolidated financial statements as revenue from operations.

7. DONATED PERSONAL PROTECTIVE EQUIPMENT (UNAUDITED)

The Company did not receive any donated personal protective equipment from the federal government during the year ended September 30, 2022.

* * * * *

Report on Internal Control Over Consolidated Financial Reporting and on Compliance and Other Matters Based on an Audit of Consolidated Financial Statements Performed in Accordance with *Government Auditing Standards*

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Battelle Memorial Institute and Subsidiaries
Columbus, Ohio:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to consolidated financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Battelle Memorial Institute and Subsidiaries ("Battelle"), which comprise the consolidated balance sheet as of September 30, 2022, and the related consolidated statements of operations, comprehensive income, equity, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated November 30, 2022.

Report on Internal Control Over Consolidated Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Battelle's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Battelle's internal control. Accordingly, we do not express an opinion on the effectiveness of Battelle's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Battelle's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Battelle's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Battelle's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

November 30, 2022

Report On Compliance For Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required By the Uniform Guidance

INDEPENDENT AUDITOR’S REPORT

To the Board of Directors of
Battelle Memorial Institute and Subsidiaries
Columbus, Ohio:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Battelle Memorial Institute and subsidiaries (“Battelle”) with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Battelle’s major federal programs for the year ended September 30, 2022. Battelle’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

In our opinion, Battelle complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to consolidated financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor’s Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Battelle and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Battelle’s compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Battelle’s federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Battelle's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Battelle's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Battelle's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- obtain an understanding of Battelle's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Battelle's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of Battelle as of and for the year ended September 30, 2022, and have issued our report thereon dated November 30, 2022, which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Deloitte & Touche LLP

June 6, 2023

BATTELLE MEMORIAL INSTITUTE

SUPPLEMENTAL SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED SEPTEMBER 30, 2022

PART I—SUMMARY OF AUDITOR’S RESULTS

Consolidated Financial Statements

Type of auditor’s report issued on whether the consolidated financial statements audited were prepared in accordance with GAAP: unmodified

Internal control over consolidated financial reporting:

- Material weakness(es) identified? _____yes X_____no
- Significant deficiency(ies) identified not considered to be material weaknesses? _____yes X_____none reported

Noncompliance material to consolidated financial statements noted? _____yes X_____no

Federal Awards

Internal control over major programs:

- Material weakness(es) identified? _____yes X_____no
- Significant deficiency(ies) identified not considered to be material weaknesses(es)? _____yes X_____none reported

Type of auditor’s report issued on compliance for major federal programs: unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? _____yes X_____no

Identification of Major Program:

CFDA Number

N/A

Name of Federal Program or Cluster

Research & Development Cluster

Dollar threshold used to distinguish between Type A and Type B programs \$3,000,000

Auditee qualified as low-risk auditee? X_____yes _____no

PART II—FINANCIAL STATEMENT FINDINGS

None noted.

PART III— FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None noted.

PART IV—SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS

None noted.